



Drug-Induced Cognitive Impairment

Arne Reimers^{1,2} · Per Odin^{3,4} · Hanna Ljung^{3,4}

Accepted: 4 December 2024
© The Author(s) 2024

Abstract

Drug-induced cognitive impairment (DICI) is a well-established, yet under-recognised, complication of many types of pharmacological treatment. While there is a large body of scientific literature on DICI, most papers are about drug-induced dementia in the elderly and one specific drug class. However, DICI also comprises subclinical symptoms, domain-specific forms of cognitive impairment as well as mild cognitive impairment (MCI), and delirium. Even mild forms of DICI, if not recognised as such, can have deleterious and life-long consequences. In addition, DICI also occurs in younger adults and in children, and has been reported with many different drug classes. The aim of this review is to raise awareness of DICI by providing an overview on the type(s) and symptoms of observed DICI and the suspected underlying mechanism(s) for various drug classes: antiseizure medications, antidepressants, antiparkinsonian drugs, antipsychotics, lithium, benzodiazepines/Z-drugs, opioids, first-generation antihistamines, drugs for urinary incontinence, proton pump inhibitors, glucocorticoids, NSAIDs, statins, antihypertensives, and chemotherapeutic agents.

Key Points

Many drug classes including non-CNS drugs have a potential to induce various degrees of cognitive impairment, acutely and chronically, and in all age groups.

While there is much research on drug-induced dementia in the elderly, milder forms of drug-induced cognitive impairment (DICI) and DICI in younger populations are less well studied.

Most clinical trials either ignore the cognitive safety of study drugs or use inadequate methods to assess it.

Given the epidemic-like global increase of dementia, more research on DICI is urgently needed.

1 Introduction

1.1 Types and Severity of Drug-Induced Cognitive Impairment

Drug-induced cognitive impairment (DICI) is a term used for a decline in cognitive functions that is primarily caused by medication. It is an unwanted, negative effect on cognitive abilities that can arise from both CNS-active agents and non-CNS-active agents. These negative effects on cognition are mediated by a multitude of pathophysiological mechanisms, as we will show in this paper. The type of cognitive impairment, its course, and its severity may therefore differ between drugs and patients.

DICI can mimic any type of cognitive impairment caused by disease or aging and may therefore be insidious in the sense that it can be interpreted as symptoms and worsening of an existing disease or as onset of a new disease or condition [1]. As we will describe later, DICI may affect functions in only one or in several cognitive domains. Memory problems are a common symptom of DICI and can present as difficulty recalling instructions or recent events or missing important appointments. Confusion or disorientation regarding space and time may occur. DICI affecting functions within the attention domain often present as being distracted and having difficulties focusing on a specific task. Slow thinking and processing speed as well as decreased reaction time and motor slowness are also common symptoms

✉ Arne Reimers
arne.reimers@med.lu.se

¹ Department of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University, Box 117, 22100 Lund, Sweden

² Department of Clinical Chemistry and Pharmacology, Skåne University Hospital, 22185 Lund, Sweden

³ Division of Neurology, Department of Clinical Sciences Lund, Lund University, Box 117, 22100 Lund, Sweden

⁴ Department of Neurology, Rehabilitation Medicine, Memory and Geriatrics, Skåne University Hospital, 22185 Lund, Sweden

of DICI. Difficulties with language and communication may occur, such as trouble finding the right words, slurred speech, or increased response latency. More elaborated cognitive tasks, such as complex problem-solving, decision making, planning, or organising activities may be affected. With medications that induce sedation, cognitive impairment may occur as a consequence of sleepiness [2].

Often, DICI manifests clinically with acute symptoms such as severe confusion or delirium. Older patients with pre-existing cognitive impairment are at particularly high risk of developing drug-induced delirium [1, 3]. The distinction between delirium and dementia may sometimes be confusing. However, the main distinguishing features of delirium are the acute onset of an impaired level of consciousness, most often accompanied by illusions or hallucinations, changes in perception as well as other acute symptoms that are not typical for dementia [4].

DICI may appear shortly (hours or days) after starting a new drug, but it can appear at any time during treatment, even after long-term use of several years. The degree of cognitive impairment correlates often, but not always, with dose or serum concentration. In most cases, altered cognitive functions normalise after dose reduction or tapering off the drug. Usually, this also applies to the more severe cases such as dementia-like states, as the underlying pathophysiology of drug-induced dementia most often is functional (as opposed to structural). However, there are exceptions to this rule and DICI may persist for months or years if structural changes have developed [5, 6].

DICI severity ranges from subtle, subclinical symptoms to mild cognitive impairment (MCI) and, finally, dementia. MCI involves some deterioration of cognitive function in at least one cognitive domain, combined with subjective complaints or observations by a proxy, with a preserved over-all cognitive functioning. By contrast, dementia is more severe in terms of objective cognitive deficits and includes loss of autonomy in several activities of daily living [7].

Clinical studies, reviews, meta-analyses, and guidelines addressing DICI tend to focus on (a) the elderly, (b) manifest dementia, and (c) drugs with anticholinergic or sedating properties. It is important to note, though, that a wide range of medications can negatively impair cognition—to varying degrees, and in all age groups.

1.2 Epidemiology

Drug-induced dementia has been estimated to account for 2.7–10% of all dementias [1, 8]. A 1988 review of 32 studies found that drugs represent the most common cause of reversible dementia, accounting for 28.2% of the cases [5]. To the best of our knowledge, no newer data are available. However, prescription rates and the individual total drug load

have increased in the last decades which means that these numbers could be higher today [9, 10]. The risk of drug-induced dementia increases with polypharmacy: three-fold with two to three drugs, nine-fold with four to five drugs, and 14-fold with more than 6 drugs [11]. The prevalence of polypharmacy (i.e., treatment with five or more drugs) is globally increasing in adults of all age groups, reaching over 60% in people aged 65 years or older in some Western countries [12–14]. Clinical experience and case reports suggest that drug-induced dementia is not always recognised as such. In such cases, the cognitive problems may continue for years [15–20].

Drugs are one of the most common causes of delirium, especially in the elderly [1, 21]. Medications with anticholinergic and sedating properties are particularly well known for this, but other drug classes can also induce delirium. In elderly, hospitalised patients, drugs have been reported as the cause of delirium in up to 30% of all cases [22]. Polypharmacy more than doubles the risk [23]. Physicians often miss drug-induced delirium which suggests that the true numbers may be even higher [21].

It must be emphasised that the above epidemiological data apply to delirium and dementia. Aside from case studies and reports, there is a lack of epidemiological data and systematic studies on milder, more subtle forms of DICI, and on DICI in younger adults and children.

Recent research suggests that 10–20% of adults aged ≥ 65 years have MCI [24]. The prevalence of dementia roughly doubles for every 5 years of age [25]. With the world population growing older, an extensive surge in MCI and dementia cases is anticipated. Projections suggest a rise from 57 million dementia cases worldwide in 2019 to 153 million cases by 2050 [26].

Drugs have been identified as a modifiable risk factor for Alzheimer's disease [27]. However, while the World Health Organization states nine factors that increase the risk of developing dementia, drugs are not mentioned [28]. Alzheimer's Disease International counts 12 modifiable risk factors for dementia except drug treatment [29]. Similarly, frequently cited reference texts or position papers do not mention drugs as a possible risk factor for MCI or dementia [26, 30, 31].

1.3 Drug-Induced Cognitive Impairment in Clinical Studies

There is a considerable amount of research on DICI, mainly addressing dementia. However, clinical trials and other studies examining the risk of DICI for certain drug classes often yield conflicting results. The main reasons for this are different study designs and inappropriate methodology, for example, short observation periods and/or the use of screening

tools instead of neuropsychological testing. Questionnaires and screening tools like the mini mental state examination (MMSE) or Montreal cognitive assessment (MoCA) have limited sensitivity and specificity. False-positive and, particularly, false-negative results as well as misclassifications are common [32–38].

In addition, only 6.5% of clinical drug trials actively assess the cognitive safety of the trial drug [39]. Of these few trials, the vast majority uses questionnaires or screening tools, which increases the risk of not detecting milder cognitive impairment, especially in younger or more well-functioning patients. In addition, it is common practice that published safety data from randomised controlled trials (RCTs) do not report adverse events that were observed in less than five percent of the participants. Thus, systematic reviews and meta-analyses using published safety data from RCTs are particularly prone to produce negative results on DICI. This is important to keep in mind when reading this review. Also, study results only apply to the studied population as a whole and, usually, to only one drug or drug class. However, a negative result on the group level does not exclude the possibility of DICI occurring with certain drug combinations, in certain subgroups, or in individual patients.

Another limitation of RCTs is the narrow scope of the populations studied because of strict inclusion and exclusion criteria. This results in a considerably reduced generalisability to the clinical population in real life, which typically exhibits greater comorbidity, greater numbers (and other types) of comedication, and more pronounced fragility [40]. Consequently, patients at higher risk of adverse events may be inadequately represented in RCTs. This may explain why certain adverse drug reactions have a much higher prevalence in real life than in RCTs [41].

From these points, there is reason to suspect that DICI is considerably under-recognised. Therefore, the aim of this review is to increase awareness. Its focus lies in describing the various drug classes' potential to induce cognitive impairment, and (possible) underlying mechanisms.

2 Literature Search Strategy

A comprehensive search strategy using various search strings was employed to identify relevant articles, including case reports, register studies, cross-sectional studies, prospective clinical studies, systematic reviews, and meta-analyses from electronic databases such as PubMed, Google Scholar, and Scopus. Combinations of keywords and phrases related to various drug classes and different forms of cognitive impairment were used to retrieve relevant literature. The search was not limited by publication date, but newer publications were preferred to ensure that this review reflects

current knowledge. Additionally, reference lists of relevant articles were reviewed to identify additional sources.

3 Drug-Induced Cognitive Impairment According to Drug Class

An overview of different drug classes, the type of associated cognitive impairment, and possible underlying mechanisms of action is given in Table 1.

3.1 Antiseizure Medications

Numerous studies have established that antiseizure medications (ASMs) can impair cognition, even at drug concentrations within the reference range [42–45]. Polypharmacy and high ASM blood levels increase the risk. However, epilepsy itself is associated with cognitive impairment. Thorough neuropsychological testing may be necessary to distinguish disease-related cognitive symptoms from DICI [46].

Antiseizure medications commonly regarded as having a relatively high risk of cognitive impairment are carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproate, topiramate, and zonisamide. They all can impair executive functions, attention, processing speed, learning, and memory [42, 44, 45]. In addition, the latter two ASMs are notorious for their potential to negatively affect speech and verbal memory [47, 48]. This distinguishes topiramate and zonisamide from other ASMs and gives them a specific cognitive profile.

ASMs generally considered as having a small risk of cognitive impairment are gabapentin, lacosamide, levetiracetam, lamotrigine, oxcarbazepine, and pregabalin [43]. For the most recent ASMs there are insufficient data. It must be noted that 'small risk' does not mean 'no risk' as most often the risk increases with the dose. However, the latter is not always the case. Lamotrigine, for example, is generally regarded as cognitively safe or even beneficial for cognition. However, case reports describe severe aphasia and rapidly progressive dementia-like condition in paediatric and adult patients even at low doses [49, 50]. Also, drugs with a small risk of cognitive impairment may still have a considerable potential to induce a range of other neurologic or psychiatric adverse effects. Levetiracetam, for instance, is not known to impair cognition. However, it is well known for inducing hostility and aggressive behaviour in both children and adults [51].

ASMs affect nerve cell excitation and communication by a large variety of molecular mechanisms. Most block ion channels or bind to various receptors. Two out of three ASMs act by amplifying GABA. Practically all ASMs possess multiple mechanisms of action and the new ASMs share many of their mechanisms with the older ASMs [52, 53]. It

Table 1 Overview of drug classes, associated type of cognitive impairment, possible underlying mechanisms, and patient groups at particularly high risk

Drug class, example drugs	Type of cognitive impairment		Possible mechanism(s)	Patient groups at high risk
	Acute	Chronic		
Antiseizure medications				
Carbamazepine, valproate, clobazepam, ethosuximide, phenobarbital, phenytoin, primidone	Impaired attention and executive functions, delirium	Impaired attention, executive functions, processing speed, learning	Reduced neuronal excitability through e.g. interaction with voltage-gated ion channels or amplification of GABA effects	Patients with neurologic or psychiatric comorbidity, pre-existing cognitive impairment, polytherapy, or high ASM serum concentrations
Topiramate, zonisamide, sulthiame		Impaired memory and speech (esp. topiramate, zonisamide)	Inhibition of carbonic anhydrase	
Antidepressants				
Tricyclic antidepressants (amitriptyline, nortriptyline, clomipramine, doxepine)	All antidepressant classes, particularly TCA: confusion, delirium	TCA: Impaired learning & memory, increased risk of MCI and dementia	TCA: anticholinergic effects, blocking of histamine receptors	All antidepressants: older adults
SSRI (citalopram, escitalopram, fluoxetine, sertraline, paroxetine)		SSRI: Low risk of chronic cognitive side-effects but reduced ability to generalise learned concepts	SSRI: hyponatremia, altered hippocampal function	Hyponatremia: women at 3× higher risk than men
NaSSA (mianserin, mirtazapine)			NaSSA; blocking of histamine receptors	
SNRI (duloxetine, venlafaxine), NDRI (bupropion)		SNRI, NDRI: reduced cognitive flexibility	SNRI, NDRI: dopaminergic and noradrenergic overstimulation	
Antiparkinsonian drugs				
Dopamine agonists (pramipexole, ropinirole)	Confusion, delirium	Fluctuating arousal, impaired attention, incoherent verbal output	Disturbed D1/D2 balance and dopamine/acetylcholine balance	Patients with existing cognitive decline and those with anticholinergic comedication
Amantadine MAO inhibitors (selegiline, rasagiline)	Delirium (amantadine and MAO inhibitors)		Unknown	
Antipsychotics				
Typical, e.g., haloperidol, flupentixol, fluphenazine, zuclopentixol	All antipsychotics: Delirium	Reduced processing speed, verbal memory, executive functions, attention, motivation (important for learning and planning), working memory, impulse control; increased risk of dementia	Anticholinergic effects (some atypical antipsychotics), antihistaminergic and antidopaminergic effects, increased risk of metabolic syndrome, reduced cortical thickness	Older adults (due to age-related factors and the prevailing polypharmacy)
Atypical, e.g., clozapine, olanzapine, risperidone, paliperidone, quetiapine, aripiprazole				
Lithium				
Lithium carbonate, lithium citrate, lithium sulfate, lithium orotate	Acute and chronic: reduced alertness and attention, impaired learning, reduced orientation and visuospatial memory, dysphasia, aphasia, acalculia, confusion, and slowed psychomotor function		Unknown. Most often but not always correlated with high plasma concentrations	Patients on polytherapy with other CNS-active drugs; older adults and others with reduced kidney function (e.g., users of NSAIDs)
Benzodiazepines and Z-drugs				
Alprazolam, clonazepam, lorazepam, diazepam, zopiclone, zolpidem	Delirium, anterograde amnesia, Reduced vigilance and psychomotor abilities	Reduced vigilance, and psychomotor abilities, increased risk of dementia	Enhancement of GABA through modulation of GABA _A -receptor function	Individuals with pre-existing cognitive impairment or other neuropsychiatric conditions (all age groups)

Table 1 (continued)

Drug class, example drugs	Type of cognitive impairment		Possible mechanism(s)	Patient groups at high risk
	Acute	Chronic		
Opioids				
Tramadol, oxycodone, hydrocodone, morphine, codeine, buprenorphine, fentanyl	Slowed reaction time, reduced attention and psychomotor abilities, disturbed consciousness, confusion, delirium	Slowed reaction time, reduced attention and psychomotor abilities, disturbed consciousness, opioid-induced amnesic syndrome, increased risk of dementia	Inhibition of adenylyl cyclase, reduced neuronal excitability through modulation of calcium and potassium channels, blockade of NMDA receptors and acetylcholine receptors, reduced neurogenesis in the hippocampus, neuronal apoptosis	Patients with existing cognitive impairment or other neuropsychiatric disorders; patients with concomitant CNS-depressant drugs; older adults
First-generation antihistamines (sleep aids)				
Hydroxyzine, promethazine, cyproheptadine, diphenhydramine	Reduced attention and learning, delirium (promethazine)	Reduced learning, reduced memory	Blockade of cerebral histamine receptors and acetylcholine receptors	Older adults, especially those with cognitive impairment and/or treated with other drugs with a potential to induce DICI
Drugs for urinary incontinence (anticholinergics)				
Tolterodine, oxybutynin, solifenacin	Delirium	Impaired learning and memory, delirium, increased risk of dementia	Blockade of cerebral muscarinic acetylcholine receptors	Older adults, especially those with cognitive impairment and/or polytherapy
Proton pump inhibitors				
Omeprazole, esomeprazole, lansoprazole, pantoprazole	Delirium	Increased risk of dementia	Hyponatraemia, inhibition of choline acetyltransferase, reduced absorption of vitamin B12 because of stomach anacidity, induction of endothelial dysfunction leading to cardiovascular damage in the brain, inhibition of carbonic anhydrase	Geriatric patients, particularly those with pre-existing cognitive impairment and/or anticholinergic comedication
Glucocorticoids				
Prednisone, prednisolone, triamcinolone, betamethasone	Delirium	Impaired attention, impaired executive functions, impaired memory, dementia	Reversible hippocampal impairment (short-term exposure to high doses); irreversible neuronal death and permanent hippocampal damage (chronic exposure)	Older adults, but individuals below 65 years of age may also be affected
Non-steroidal anti-inflammatory drugs (NSAIDs)				
Meloxicam, diclofenac, naproxen, ibuprofen, ketorolac, celecoxib	Acute dementia (rare), delirium (rare)	Increased risk of dementia	Cerebral hypoperfusion through vasoconstriction and/or thrombophilia; microstrokes	Older adults, especially those with anticholinergic comedication

Table 1 (continued)

Drug class, example drugs	Type of cognitive impairment		Possible mechanism(s)	Patient groups at high risk
	Acute	Chronic		
<i>Statins</i>				
Atorvastatin, simvastatin, rosuvastatin, pravastatin	Confusion, amnesia	Dementia-like conditions	Impaired cell membrane function, impaired myelin function, decreased cholesterol in the hippocampus, reduced synthesis of coenzyme Q10	Elderly patients, especially those with pre-existing cognitive impairment; those with other memory-affecting comedication
<i>Antihypertensives and drugs with hypotensive effects</i>				
ACE inhibitors, AT2 antagonists, calcium blockers, β-blockers, diuretics, nitrates, tricyclic antidepressants, antipsychotics, dopaminergic antiparkinsonian drugs, benzodiazepines, opioids, SGLT-2 inhibitors	Confusion	Cognitive deficits in various domains (mainly executive and memory functions; dementia-like conditions)	White and grey matter damage through cerebral hypoperfusion/ ischaemia	Patients with orthostatic hypotension
<i>Chemotherapeutic agents</i>				
Methotrexate, mercaptopurine, 5-fluorouracil, gemcitabine, cyclophosphamide, doxorubicin, cisplatin, paclitaxel, interferon	Acute and long-term cognitive impairment, especially impaired attention, memory, executive functions and processing speed, even months after last treatment		Induction of proinflammatory cytokines and inflammation-related oxidative stress, damage to the blood–brain barrier, decreased hippocampal neurogenesis	Patients with CNS tumours; those with advanced cancer; those with psychoactive medications such as opioids, benzodiazepines, corticosteroids, etc.; elderly patients, especially those with dementia

For detailed information and references, please see article text

ASM anti-seizure medication, *DICI* drug-induced cognitive impairment, *MAO* monoamine oxidase, *NaSSa* noradrenergic and specific serotonergic antidepressants, *NDRI* noradrenaline and dopamine reuptake inhibitors, *SNRI* serotonin and noradrenaline reuptake inhibitors, *SSRI* selective serotonin reuptake inhibitors, *TCA* tricyclic antidepressants

is therefore difficult to ascribe their cognitive effects—or lack thereof—to a specific mechanism of action. It is noteworthy, though, that only topiramate, zonisamide, and sulthiame inhibit carbonic anhydrase and all three drugs impair cognition, especially verbal memory [53, 54].

Acute and chronic effects: Usually, symptoms of cognitive impairment by ASMs develop gradually over weeks to months. However, patients may present with various acute cognitive symptoms at any time after treatment initiation, such as considerably reduced executive functions, aphasia, delirium, and even neurological symptoms resembling stroke, especially after rapid dose titration or after substantial dose increases [55–57].

Patient groups at high risk: Patients with neurologic or psychiatric comorbidity, pre-existing cognitive impairment, polytherapy, or high ASM serum concentrations (possible even at normal doses if an ASM is combined with an enzyme inhibitor).

3.2 Antidepressants

Depression is associated with reduced cognitive function in several cognitive domains. It can therefore be difficult to distinguish such cognitive impairment from adverse drug effects. While many studies did not find an increased risk of dementia with antidepressant use or even beneficial effects, other studies did [58–61]. Moreover, as mentioned above, DICI is not only manifest dementia.

Tricyclic antidepressants are well known for their negative impact on cognition. This is usually ascribed to their strong anticholinergic properties. However, tricyclics also have considerable antihistaminergic properties. It is well-known that blocking cerebral histamine receptors, especially the H₁-receptor, induces sedation and sleepiness which inevitably impairs attention and cognitive speed. The role of histamine in the pathogenesis and pharmacological treatment of depression has recently gained attention [62]. However, aside from its role in the sleep-wake rhythm, histamine also has an important role in cognitive functioning [63]. Blocking of these receptors by tricyclic antidepressants may therefore contribute to their negative cognitive effects. The American Geriatrics Society recommends that tricyclics (plus paroxetine, a selective serotonin reuptake inhibitor [SSRI] with anticholinergic properties) be avoided in older patients [64].

Non-tricyclic, modern antidepressants have long been regarded as either cognition neutral or cognition improving [65, 66]. However, it is unclear whether the latter is a direct effect. As depression itself is generally associated with impaired cognition, including dementia-like conditions, relieving a person from depression may improve their cognitive problems as well. Moreover, newer research indicates that cognitive impairment is common during treatment with newer antidepressants and that it may resemble adverse drug

effects rather than residual symptoms of depression [67–71]. This notion is supported by the observation that SSRIs may impair cognitive function even in healthy subjects [72].

Modern antidepressants may induce cognitive impairment by various mechanisms. Practically all classes of antidepressants, including tricyclics, commonly induce hyponatraemia, a condition that leads to various neurological symptoms including confusion, cognitive impairment and delirium [73–75].

Paroxetine, an SSRI, can induce cognitive impairment through its strong anticholinergic properties [64, 76, 77] and deteriorate hippocampal functioning, possibly by induction of excessive neurogenesis in the dentate gyrus which produces cells that behave differently from those cells naturally generated in the dentate gyrus [78].

Noradrenergic and specific serotonergic antidepressants (NaSSAs) like mianserin and mirtazapine are known to produce fatigue and may impair attention, speed and visuospatial ability through their pronounced antihistaminergic properties [79–81]. Mianserin produced slowed reaction time and reduced psychomotor function in healthy subjects while mirtazapine may reduce driving ability [82–84].

The positive effects of dopamine and norepinephrine on cognition (in patients with ADHD) follow an inverse U-shaped dose–effect curve, meaning that too much stimulation may impair cognition, particularly cognitive flexibility. This has been demonstrated for central stimulants like methylphenidate or amphetamine [85, 86]. Because of their strong pharmacological similarities with central stimulants, it may also apply to noradrenaline and dopamine-enhancing antidepressants, that is, noradrenaline and dopamine reuptake inhibitors (NDRIs) like bupropion as well as serotonin and noradrenaline reuptake inhibitors (SNRIs) like venlafaxine or duloxetine (the latter two drugs also block the reuptake of dopamine) [87–89].

Acute and chronic effects: Anticholinergic cognitive effects (mainly memory-related) and antihistaminergic effects (mainly sedation and impaired learning) may manifest within days after start of treatment. Symptoms of dopaminergic/noradrenergic overstimulation in the form of reduced cognitive flexibility may occur within days to weeks. Hyponatraemia, often leading to acute symptoms like confusional state or delirium, may occur at any time after treatment initiation—one study reported a median time to onset of hyponatraemia of 13 days, ranging from 3 to 120 days [90].

Patient groups at high risk: Older adults are particularly susceptible to DICI by antidepressants. Women appear to be at a two to three times higher risk for antidepressant-induced hyponatraemia than men [90, 91].

3.3 Antiparkinsonian Drugs

The loss of dopamine in Parkinson's disease often causes cognitive decline and in some, Parkinson dementia. Without neuropsychological testing, it can be demanding to distinguish disease-related cognitive impairment from DICI [35]. Parkinson's disease is commonly treated with dopaminergic drugs and, sometimes, anticholinergic drugs like trihexypenidyl, biperiden or benztropine.

The deleterious effects of anticholinergic drugs on cognition are undisputed and reviewed elsewhere in this paper [64, 92].

Dopaminergic drugs comprise L-DOPA, dopamine agonists as well as monoamine oxidase (MAO) and catechol-*O*-methyltransferase (COMT) inhibitors. While there is much focus on psychiatric and behavioural adverse effects of dopaminergic treatment, DICI is less recognised. L-DOPA, unlike common dopamine D2/D3 agonists, can enhance learning, working memory, and executive functions. This has been ascribed to the fact that dopamine binds to both D1 and D2 receptors whereas dopamine agonists mainly bind to D2 and D3 receptors [93]. D1 receptors, involved in phasic dopaminergic stimulation, are crucial for things like working memory and learning. This may explain why L-DOPA has a cognition-improving effect while dopamine agonists do not. To the contrary, several studies suggest that dopamine agonists, either in monotherapy or combined with L-DOPA, might impair cognitive function after a single dose [94–98]. However, both L-DOPA and dopamine agonists can induce confusional or delirious states with fluctuating arousal, impaired attention, and incoherent verbal output, especially in combination with anticholinergic drugs. Frequencies of 5–25% have been reported, and the risk is higher with dopamine agonists than with L-DOPA [22, 99]. Delirium is also common with amantadine or MAO inhibitors [99].

As dopaminergic treatment can induce psychotic and obsessive-compulsive symptoms as well as reduced impulse control, treatment with antipsychotics may become necessary. Among the most used antipsychotics in Parkinson's disease are clozapine and quetiapine, mainly because of their weak antidopaminergic properties. However, clozapine has strong anticholinergic and antihistaminic effects. Quetiapine has weaker anticholinergic effects but has pronounced antihistaminic properties. This may explain the observed impairments in processing speed, verbal memory, and executive functions with these drugs, even at normal doses [100–105]. However, these findings possibly do not apply to patients with Parkinson's disease as effective doses and serum concentrations usually are far below those used in schizophrenia and related disorders [106].

Acute and chronic effects: Dopamine agonists may impair cognitive function at any time. Usually, these effects develop

gradually over weeks. However, in healthy subjects they were observed after a single therapeutic dose.

Patient groups at high risk: Patients with existing cognitive decline and those with anticholinergic comedication.

3.4 Antipsychotics

Schizophrenia and schizoaffective disorders are associated with a wide range of cognitive impairment which may make it difficult to assess possible negative effects of antipsychotic drug treatment on cognition [107]. In parallel with depression, treating the underlying disease often improves cognitive function, but antipsychotics may also exert detrimental effects on cognition, even at low doses [108].

Antipsychotics bind to a variety of receptors including dopamine, norepinephrine, serotonin, histamine, and muscarinic acetylcholine receptors. Second-generation antipsychotics do so with great variation in affinity, which gives each of these drugs a distinct receptor profile [109].

Typical or first-generation antipsychotics all have strong dopamine D2-antagonistic properties. Dopamine plays an important role in cognition and is involved in, for example, attention, motivation (important for learning and planning), working memory, processing speed, and impulse control [85]. Cognitive adverse effects of typical antipsychotics have been documented in animal models, healthy subjects, and patients with schizophrenia [110]. Chlorpromazine and thioridazine, in addition, have strong anticholinergic and antihistaminergic properties which impair processing speed and memory functions. Other first-generation antipsychotics do not have noteworthy anticholinergic effects.

Atypical or second-generation antipsychotics also block dopamine D2 receptors, although with lower affinity, and some of them only as partial antagonists. They typically bind with varying affinity to different serotonin (5-HT) receptors, thereby modifying dopaminergic neurotransmission [109, 111].

Clozapine, quetiapine (see Sect. 3.3 *Antiparkinsonian Drugs*), and olanzapine also have strong anticholinergic properties. This gives them not only the potential to impair cognition, particularly memory functions, but also a potential to induce acute delirium. Olanzapine and quetiapine, in addition, exert strong antihistaminic effects which explains why they are used as sedatives, usually at doses lower than antipsychotic doses. The combination of antidopaminergic and anticholinergic properties, even without antihistaminergic effects, increases the cognitive risk [112–115]. A retrospective study with over 300,000 patients found that atypical antipsychotics increased the risk of developing Alzheimer's disease by 24% [116].

Aside from their effects on dopaminergic, cholinergic, and histaminergic neurotransmission, antipsychotics may

impair cognition by several other mechanisms. Atypical antipsychotics have a demonstrated potential to induce metabolic syndrome. Obesity is associated with impaired insulin regulation, hyperlipidaemia, and vascular damage, factors known to decrease cognitive function [117, 118].

Several studies, among them double-blind, placebo-controlled ones, found significantly reduced cortical thickness after treatment with antipsychotics, especially in the prefrontal cortex [119–124]. The underlying mechanisms are unclear. While vascular damage may lead to an undersupply of nutrients and oxygen, some data also point to altered regulation of gene expression (i.e., epigenetic changes) [125]. Interestingly, cortical thinning was positively correlated with higher cumulative intake of typical antipsychotics but less with atypical antipsychotics [126]. This may be caused by the atypical antipsychotics' interference with cholesterol metabolism as cholesterol is essential for the myelination of both white and grey matter [121].

Acute and chronic effects: Acute cognitive impairment due to antihistaminergic effects (mainly sedation and impaired learning) and anticholinergic effects (mainly impaired memory) may occur at any time after start of treatment. Antipsychotics, particularly atypical ones with strong anticholinergic effects, can induce acute delirium. Chronic treatment increases the risk of developing dementia.

Patient groups at high risk: Older adults (due to age-related factors and the prevailing polypharmacy).

3.5 Lithium

Lithium is a chemical element. While there are several hypotheses on how it may exert its therapeutic effects, it is not exactly known by which molecular mechanisms it does so [127]. Adverse effects of lithium are well described in the literature [128]. Regarding cognition, data are conflicting. Many studies found a neuroprotective and cognition-enhancing effect of lithium while other studies and case reports suggest that lithium can impair cognition even at normal plasma concentrations and without other signs of lithium toxicity [127, 129–134]. Symptoms are highly variable, acute or chronic, and may include reduced alertness and attention, impaired learning, reduced orientation and visuospatial memory, dysphasia, aphasia, acalculia, confusion, slowed psychomotor function, or acute delirium. If such symptoms manifest despite normal lithium blood levels, an EEG may reveal lithium toxicity [135].

Acute and chronic effects: Acute lithium-induced DICI due to high serum concentration may occur at any time during treatment and is usually accompanied by other neurological symptoms. However, lithium-related DICI despite normal serum concentration and chronic cognitive impairment lasting for months or years has also been reported [133, 134, 136].

Patient groups at high risk: Patients on polytherapy with other CNS-active drugs; older adults and other patients with reduced kidney function including users of NSAIDs.

3.6 Benzodiazepines and Z-Drugs

These drugs amplify physiological GABAergic neurotransmission through modulation of the GABA_A receptor. This induces anxiolytic effects, reduced vigilance and psychomotor abilities, sedation, and sleepiness [137, 138]. It can also induce anterograde amnesia [139, 140]. Such effects may impair various cognitive domains, especially in the elderly [141–143]. Dementia-like states have been reported [144–146]. Administration of benzodiazepines to older adults hospitalised after major surgery is associated with increased postoperative delirium [147]. Even if only taken at bedtime, the long half-life of common benzodiazepines produces pharmacologically relevant plasma levels during daytime. The American Geriatrics Society recommends for various reasons that these drugs be avoided in the elderly, including the risk of falls [64]. Z-drugs are used as hypnotics, meaning they are only taken at bedtime. They have much shorter half-lives than common benzodiazepines (1–5 h vs 6 to >24 h), and therefore the risk of being cognitively impaired in the daytime is considerably lower [138, 148]. However, the American Geriatrics Society recommends avoiding their use in older patients for the same reasons as benzodiazepines [64].

Acute and chronic effects: In drug-naïve subjects, the cognitive effects of benzodiazepines and Z-hypnotics may manifest after a single dose. Administration of benzodiazepines to hospitalised older adults is associated with a significant risk of delirium. With chronic treatment, most people develop some degree of tolerance. However, chronic treatment may have a cumulative negative effect on cognitive function and is associated with an increased risk of developing dementia [145, 146].

Patient groups at high risk: People with pre-existing cognitive impairment or other neuropsychiatric conditions (all age groups).

3.7 Opioids

Like other neurological and psychiatric conditions, pain itself is associated with impaired cognition, which can make it difficult to identify DICI, especially its milder forms [149]. However, it is well documented that opioids can produce slowed reaction time, reduced psychomotor abilities, reduced attention, disturbed consciousness, confusion, or delirium [36, 150–152]. This can occur at normal doses, and even when administered as a patch [153]. These symptoms are often accompanied by psychiatric symptoms such

as anxiety or hallucinations. A well-known phenomenon is postoperative confusion or delirium. Many patients who wake up after surgery are confused and disorientated for some time, but reduced verbal recall and impaired arithmetic fluency have also been reported [154]. Opioid use outside clinical settings increases the risk of workplace accidents [155]. Recently, opioid-induced amnesic syndrome has emerged as a complication of opioid abuse. It has mainly been reported with fentanyl and is associated with hippocampal damage, but other cortical and subcortical structures like the basal ganglia or the cerebellum are also often involved [156–158].

Opioids exert their pain-relieving effect mainly through binding to opioid receptors in the CNS. These receptors are coupled to inhibitory G-proteins. All three major receptor subtypes (μ , κ , and δ) thus inhibit adenylyl cyclase, thereby disrupting certain intracellular signalling pathways and decreasing intracellular energy levels. In addition, opioids modulate calcium and potassium channels and produce hyperpolarisation which prevents neuronal excitation and propagation of action potentials [159, 160]. Besides binding to opioid receptors and ion channels, opioids also block glutamatergic NMDA receptors and muscarinic acetylcholine receptors [160, 161]. These mechanisms of action may explain their analgesic effect as well as their sedative properties and their negative effects on cognition [162].

Cognitive effects of long-term opioid use are less well studied than acute effects, but there are some experimental and clinical data. For example, several studies have shown that opioids reduce neurogenesis in the hippocampus (for a review, see [163]). Prolonged, but not acute, exposure to morphine may induce neuronal apoptosis [164]. While most clinical studies did not find any effect of opioids on the risk of developing dementia, newer studies, including controlled prospective and paediatric studies, have shown a slightly to considerably increased risk [165–168]. A large Danish register-based study found that new opioid use in older adults with dementia is associated with a significantly increased risk of death, including an 11-fold increase in the first 2 weeks [169].

Acute and chronic effects: See preceding text.

Patient groups at high risk: Patients with existing cognitive impairment or other neuropsychiatric disorders; patients with concomitant CNS-depressant drugs; older adults.

3.8 First-Generation Antihistamines (Sleeping Aids)

First-generation antihistamines, such as hydroxyzine, promethazine, cyproheptadine or diphenhydramine, have profound sedating effects that are therapeutically used in sleeping disorders. However, these drugs have long half-lives, and even if taken at bedtime, they may exert their effects at daytime as well, often producing drowsiness. The effect is

mediated by blockade of central H1 receptors. Drowsiness alone may affect cognition. In addition, histamine as a neurotransmitter is not only important for keeping us awake, but also plays a central role in cognition, especially learning [63]. Besides that, several first-generation antihistamines have strong anticholinergic properties. The combination of antihistaminic and anticholinergic effects resembles a high risk of cognitive impairment, particularly reduced learning and memory [170, 171]. These drugs should be avoided in the elderly [64].

Acute and chronic effects: Sedation and consecutive negative cognitive effects such as reduced attention may manifest after one dose. Chronic treatment may lead to direct and long-lasting negative effects on learning and memory.

Patient groups at high risk: Older adults, especially those with cognitive impairment and/or treated with other drugs with a potential to induce DICI.

3.9 Drugs for Urinary Incontinence

Traditionally, drugs for urinary incontinence act by blocking muscarinic M3 receptors on the urine bladder, thus reducing smooth muscle tone. Tolterodine, oxybutynin, and solifenacin are common representatives of this drug class. They pass through the blood–brain barrier and bind to neuronal M1 and M3 receptors with similar affinity as to peripheral M3 receptors [172]. As these receptors are predominantly found in the cortex and the hippocampus, their blocking impairs cognitive functions, particularly memory functions (learning and retrieval), and may lead to dementia-like conditions.

These drugs are classified as drugs with a high anticholinergic burden which means their use poses a high risk of cognitive impairment, delirium, and the development of dementia including Alzheimer's [171, 173–177]. The risk of dementia increases with greater exposure, possibly even 15–20 years before a diagnosis. However, some studies did not find negative cognitive effects. These studies tended to have shorter follow-up periods or were cross-sectional studies [176].

These drugs should be avoided in the elderly because of their recognised potential to induce cognitive impairment including delirium and dementia [64]. Despite such recommendations from the American Geriatrics Society and others, nearly one-third of dementia patients have urinary incontinence and over one-fourth of them use antimuscarinic drugs [178]. Because of these drugs' potential to impair cognition (and other bothersome anticholinergic adverse effects such as dry mouth etc.), a different class of drugs for urinary incontinence has been developed— β -3-receptor agonists like mirabegron. According to current (limited) knowledge, they do not affect cognition negatively [179].

Acute and chronic effects: Acute delirium may manifest as early as 1 week after treatment initiation but may occur at any time during treatment [180]. Non-acute cognitive effects often start to develop gradually after several weeks of treatment but may manifest earlier or later than that.

Patient groups at high risk: Older adults, especially those with cognitive impairment and/or polytherapy. However, even adults younger than 65 years may experience memory problems.

3.10 Proton Pump Inhibitors

Proton pump inhibitors (PPIs) are notoriously overprescribed, and in many countries, they can be purchased without a prescription [181]. It is not uncommon that patients use these drugs for years. Most meta-analyses did not find conclusive evidence for negative cognitive effects of PPIs. However, one recent, large prospective study demonstrated a 33% increased risk of dementia after use of PPIs for 4.4 years or more [182]. This suggests that cognitive impairment by PPIs is a chronic effect and implies a role of cumulative dose. The results of this study are in agreement with naturalistic studies that found a 44–170% risk increase for cognitive impairment including dementia, dependent on population, comorbidity, and treatment duration [183–186]. Various mechanisms may be responsible for this, the most important one being strong inhibition of cholinacetyltransferase, the enzyme that synthesises acetylcholine. PPIs inhibit this enzyme with high selectivity and high potency, and at concentrations far below their therapeutic plasma and brain concentrations [187]. A second important mechanism may be the reduced absorption of vitamin B12 because of the anacidity of the stomach [188, 189]. Vitamin B12 plays an important role in neuronal health and has been implied in the pathogenesis of Alzheimer's disease [190]. Yet another possible mechanism is the induction of endothelial dysfunction which may lead to cardiovascular damage in the brain [191]. Further, PPIs inhibit carbonic anhydrase [192, 193]. Antiseizure medications that inhibit carbonic anhydrase are well known for their pronounced negative effects on cognition, especially verbal memory (see Sect. 3.1 *Antiseizure Medications*), while carbonic anhydrase activators are currently being researched for possible neuroprotective effects [194]. Finally, PPIs can induce acute delirium via disturbed electrolyte homeostasis such as hypomagnesaemia, hyponatraemia, or hypokalaemia. This may occur after only one day of treatment [195–197]. It is likely, though, that the anticholinergic effects described herein play a causal role in delirium as well.

Acute and chronic effects: One study found that use of PPIs was associated with a 67% increased risk of developing delirium in geriatric patients [198]. Long-term treatment is associated with an increased risk of developing dementia.

Patient groups at high risk: Older adults, particularly those with pre-existing cognitive impairment and/or anticholinergic comedication.

3.11 Glucocorticoids

Elevated cortisol levels are involved in the pathogenesis of delirium, dementia, and age-related cognitive decline. Cerebral atrophy, sometimes irreversible, has long been known as a consequence of treatment with steroids, particularly high-dose treatment [199, 200]. The hippocampus has a high density of glucocorticoid receptors. While short-term exposure to high levels of glucocorticoids may cause reversible hippocampal impairment, chronic exposure may lead to irreversible neuronal death and permanent hippocampal damage [201–204]. Accordingly, patients receiving chronic treatment with glucocorticoids have reduced hippocampal volumes and exhibit declarative memory deficits [205]. Negative effects on cognition, particularly memory functions, have also been reported in children [206]. Aside from impaired memory functions, executive functions and attention may also be negatively affected [22].

Varney et al. coined the term *steroid dementia* in their 1984 report on six patients (25–65 years old) that experienced dementia without psychotic symptoms while being treated with glucocorticoids [207]. Since then, glucocorticoid-induced cognitive impairment, often mimicking Alzheimer's, has repeatedly been reported in the literature. Reversal of these symptoms may take from a few weeks to almost a year after stopping treatment [19, 22, 208–210].

Acute delirium is common with glucocorticoid treatment. A meta-analysis of 49 studies found that 16% of patients develop delirium [211].

Despite these well documented effects, a recent meta-analysis of 43 RCTs with glucocorticoids found that only one of them looked at possible treatment-emergent cognitive impairment, in line with the recent finding that cognitive safety is largely ignored in RCTs. By contrast, more than half of 22 studies designed to examine adverse cognitive effects of glucocorticoids reported impaired cognition, predominantly memory-related functions (indicating hippocampal damage) [39, 210].

Patient groups at high risk: Older adults, but individuals below 65 years of age may also be affected.

3.12 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Non-steroidal anti-inflammatory drugs (NSAIDs) may produce cognitive adverse reactions after a single dose [212, 213]. Interestingly, NSAIDs have been extensively studied as potential protective agents against cognitive decline. For

various reasons, the results of these studies have been mixed [214].

Only few studies examined if NSAIDs may induce DICI, and they focused on manifest dementia only. One large study enrolled 2736 dementia-free participants with extensive pharmacy data even from before enrolment and then followed them every other year for up to 12 years. Compared with nonusers and light users, heavy NSAID users had an increased occurrence of dementia (1.7-fold increased) and Alzheimer's disease (1.6-fold increased) [214]. Heavy use was defined as at least 500 prescribed daily doses within 2 years, equivalent to about five doses a week. Other studies produced negative results. However, they had considerable methodological weaknesses such as short follow-up time or up to 45% of included patients younger than 65 years [215, 216]. In addition, pain itself is associated with impaired cognition [217]. Hence, it can be difficult to identify milder forms of DICI in pain patients, especially with screening tools like the mini mental state examination (MMSE) or the Montreal cognitive assessment (MoCA).

It is not fully understood how NSAIDs may impair cognition. It is possible that NSAIDs have pharmacological effects that have not yet been discovered or that have not been fully elucidated. For example, only recently has it been found that NSAIDs may inhibit the breakdown, and thus prolong the effect, of endocannabinoids [218, 219]. Also, there could be distinct mechanisms for acute and chronic cognitive effects.

Considering the biological effects that we do know most about (inhibition of cyclooxygenase [COX]-1 and -2), the most probable explanation for NSAID-induced cognitive impairment would be that NSAIDs reduce the blood flow to, and within, the brain. This would resemble a parallel to their negative effect on renal blood flow and their potential to induce thrombotic cardiovascular events, that is, constriction of arterioles and enhanced aggregation of thrombocytes [220–222]. These mechanisms may cause DICI through acute or chronic neuronal undersupply of nutrients and oxygen as well as unnoticed multiple small strokes.

Acute and chronic effects: Acute treatment may lead to impaired cognition and neurological symptoms. Optic neuritis with visual field defects after short-term use as well as tunnel vision followed by an altered state of consciousness after a single dose of ibuprofen have been reported [212, 223]. Acute states of pseudo-dementia have been observed after one week of treatment [213]. While several cases have been reported, delirium seems to be a rare complication [224]. Long-term treatment is associated with a 70% increased risk of developing dementia including Alzheimer's.

Patient groups at high risk: Elderly patients.

3.13 Statins

Cholesterol is an integral part of cell membranes and, as such, important for nerve cell communication [225, 226]. Cholesterol metabolism in neurones and glia cells also plays an important role in memory function. Importantly, cholesterol constitutes around 40% of myelin [227]. Cholesterol is poorly water-soluble and transported in the blood stream as cholesterol-containing lipoproteins (i.e., LDL- and HDL-cholesterol). These do not pass the blood–brain barrier easily. Hence, neurones and glia cells produce their own cholesterol. As brains get older, cholesterol production and myelin formation decrease, both factors contributing to memory deterioration. In Alzheimer's disease, there is a reduction in cholesterol production and its turnover in the brain [225].

Statins pass the blood–brain barrier. Once in the brain, statins reduce cholesterol synthesis the same way they do in the liver [226]. Like with all drugs, the ability of statins to pass over the blood–brain barrier correlates with their lipophilicity. The most lipophilic statin is cerivastatin, followed by simvastatin. The least lipophilic statins are pravastatin and rosuvastatin [226, 228].

By the same mechanism that reduces cholesterol synthesis, statins also reduce the synthesis of coenzyme Q10 (ubiquinone). Coenzyme Q10 has several biological functions, one of which is acting as an intracellular antioxidant. A deficit of coenzyme Q10 may thus contribute to increased neuroinflammation [229, 230].

The effect of statins on cognition is a matter of debate because clinical studies, systematic reviews, and meta-analyses produced conflicting results [231]. It is, however, established that impaired lipid metabolism can affect brain myelination [121]. Moreover, one should distinguish between acute and long-term effects of statins on cognition as they possibly (a) are caused by different mechanisms and (b) may apply to patients with different clinical characteristics [232]. Also, it is possible that statins affect cognitive function by acting on other targets than the cholesterol synthesising enzyme (HMG-CoA reductase), or by (as yet unidentified) indirect mechanisms.

Acute and chronic statin-induced memory loss/amnesia has been documented by numerous case reports, some of them with a so-called challenge-dechallenge-rechallenge design [233–236]. In some patients, a diagnosis of dementia or Alzheimer's disease was reversed after stopping the statin [237]. In 2012, the American Food and Drug Administration obliged manufacturers of statins to include reversible cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) in the prescribing information for statins [238]. The hippocampus plays a crucial role in memory functions. Mice receiving chronic simvastatin treatment showed a deficiency in recognition and spatial

memory. Imaging studies in these animals revealed a significant decrease of cholesterol in the hippocampus [239].

Regarding long-term effects, several studies found that statins induce cognitive decline [237, 240, 241]. However, many reviews, meta-analyses and position papers did not find detrimental effects and conclude that the beneficial vascular effects of statins outweigh potential cognitive risks [41, 232, 242–246]. Methodological issues, including the documented neglect and underreporting of DICI in RCTs, may explain these divergent results [39]. Moreover, statins may exert a positive effect on cognition by preventing the development of vascular dementia [232]. However, while statins may have a modest effect in slowing the progression of cognitive decline in patients with AD, randomised controlled trials failed to support the beneficial effect of statins in lowering the risk of dementia [225].

Acute and chronic cognitive effects: Statins seem to mainly affect memory functions. Reversible acute amnesia after days to weeks of treatment has frequently been reported. Chronic treatment (months to years) may lead to dementia-like conditions.

Patient groups at high risk: Elderly patients, especially those with existing MCI or dementia (high risk of non-detection of DICI); patients with other cognition-impairing drugs, especially those that affect memory (mainly drugs with anticholinergic effects).

3.14 Antihypertensives and Drugs with Hypotensive Effects

Adequate treatment of hypertension may have a protective effect against dementia but not necessarily against milder forms of cognitive decline [247, 248]. However, hypotension is a common complication of treatment with antihypertensives including β -blockers and diuretics. It is also seen with vasodilating nitrates, tricyclic antidepressants, antipsychotics, dopaminergic antiparkinsonian drugs, benzodiazepines, opioids, and SGLT-2 inhibitors [249–253]. Antihistamines (e.g., diphenhydramine, cetirizine) and herbal supplements (e.g., hawthorn) have only weak to modest hypotensive effects but these may add to hypotensive effects of other drugs [254–258]. Hypotension, often clinically presenting as orthostatic hypotension, is common in hypertensive adults and in the elderly, with prevalences ranging from 3.3 to 58% [259–261]. In institutionalised elderly individuals, the prevalence is up to 70% [250].

Individuals with orthostatic hypotension, regardless of age, exhibit deficits in verbal memory and sustained attention. These deficits are predictors of a cognitive decline that surpasses what is typically expected from normal aging [262]. Clinical studies, systematic reviews, and meta-analyses have demonstrated that orthostatic hypotension is associated not only with dizziness but also with falls, ischemic

strokes, cognitive impairment, dementia, and increased mortality [249, 260, 263]. Cognitive deficits may manifest in various domains; mainly executive and memory functions are affected.

Acute and chronic effects: It should be noted that acute cognitive effects of orthostatic hypotension may be masked if patients are in the supine position but can become acutely evident when they change to the upright position. This has been reported even in normotensive patients without white matter changes [262]. Chronic hypotension may cause cognitive impairment including dementia, mediated by white and grey matter damage through cerebral hypoperfusion and ischaemia [254–258].

Patient groups at high risk: Patients in all age groups with normotensive or hypotensive orthostatic hypotension.

3.15 Chemotherapeutic Agents

Patients treated for CNS and non-CNS cancers often report cognitive symptoms such as impaired attention, memory, executive functions, and processing speed. This is commonly called cancer-related cognitive impairment (CRCI). CRCI is very frequent in both adults and children; for example, 15–25% of breast cancer patients show objective cognitive impairment after chemotherapy, as well as up to 32% of children with acute lymphoblastic leukaemia [264–266].

Patients commonly refer to CRCI as ‘chemofog’ or ‘chemobrain’. However, some patients may already have cognitive problems before treatment, especially those with CNS tumours. Receiving a cancer diagnosis and related treatment can be emotionally distressing. An association between depression or anxiety and cognitive complaints by cancer patients has been found in many studies [6, 267]. On the other hand, a solid body of evidence shows that cancer treatment can induce acute and long-term cognitive impairment [6, 264, 266]. Patients typically return to baseline within 6 months to 2 years post-treatment, although nearly one-third may experience persistent cognitive dysfunction [266, 268]. Interestingly, one meta-analysis on long-term cognitive outcome in cancer survivors found CRCI in cross-sectional studies but not longitudinal studies. This was probably caused by methodological issues including a practice effects of repeated neuropsychological testing [269].

A variety of mechanisms for drug-induced CRCI have been suggested [270]. Most importantly, chemotherapy can trigger an inflammatory response in the body, including the brain. High levels of proinflammatory cytokines are associated with cognitive dysfunction [268, 271]. Inflammation-related oxidative stress can damage neurones and glia cells [6, 272]. Furthermore, the blood–brain barrier becomes leaky, allowing harmful agents to enter the brain [273]. Second, most cancer drugs that enter the brain decrease hippocampal neurogenesis. This impairs cognitive function,

especially learning and memory [274]. Third, cancer treatment with cytokines like interferon- α can produce cognitive impairment including memory disturbances [275]. Fourth, hormone therapies for breast or prostate cancer reduce sex hormone production or act antagonistically on sex hormone receptors. However, these receptors are also found in the brain's cortex and in the hippocampus where they play a role in cognitive function. Thus, it is possible that such therapies induce or contribute to CRCI [6, 268].

Acute and chronic effects: Delirium is a common complication in cancer patients. CRCI is even more common.

Patient groups at high risk: Patients with CNS tumours; those with advanced cancer; those with psychoactive medications including opioids, benzodiazepines, corticosteroids; elderly patients, especially those with dementia.

4 Discussion and Conclusions

The aim of this review was not to weigh the pros against the cons, to impose dos and don'ts, or to quantify any risks, but rather to demonstrate that cognitive impairment may be induced by many different drug classes, and to raise awareness. While the evidence level is highly variable, many drug classes have a demonstrated potential to induce, or are associated with an increased risk of various acute and chronic types of cognitive impairment. Compared with research on delirium or manifest dementia in the elderly, there is little research on milder forms of DICI, especially in younger populations. It cannot be stressed enough that DICI is not synonymous with dementia or delirium, and that it occurs not only in the elderly but also in younger adults and in children, for example reduced verbal memory induced by antiseizure medications. While a false diagnosis of dementia stands out as the worst case, even subtle forms of DICI can have deleterious, life-long consequences if they are not recognised correctly. Missed degrees and careers due to reduced performance in school or university, losing work, broken relationships, losing the right to care for one's child or to manage one's own private economy are examples of such consequences.

Moreover, much of the published research on DICI consists either of observational studies or of meta-analyses of clinical trials. The inherent limitations of observational studies are well known. It is, thus, very unfortunate that there is a considerable lack of high-quality cognitive data on DICI from prospective, controlled clinical trials: only 6.5% of clinical drug trials actively assess the cognitive safety of the trial drug. Of those few trials, most use inadequate methods and have a significant publication bias leading to underreporting of DICI [39]. This makes systematic reviews and meta-analyses prone to produce false-negative results.

It is unlikely that drug manufacturers are not aware of the problem posed by inadequate cognitive assessment methods. This is illustrated by the fact that drug trials intended to demonstrate beneficial cognitive effects of the trial drug consistently use extended neuropsychological test batteries instead of simple screening instruments like the MMSE or MoCA (the authors; data obtained from www.clinicaltrials.gov).

Given the above and given the epidemiology of cognitive impairment including its predicted future development, more research on DICI is urgently needed. Primarily, regulatory authorities should require an active assessment of cognitive function in all drug trials, performed with adequate methods. Like monitoring of cardiovascular function and lab values, active monitoring of cognitive function should be part of all drug trials. Relying on spontaneous reporting or the sole use of questionnaires or screening tools such as the MMSE or MoCA to assess the cognitive safety of drugs is inadequate. We recommend specific assessment of each cognitive domain. Ideally, an experienced neuropsychologist should select the tests. This should be mandatory for drugs known to, intended to, or suspected to affect the CNS, including drugs with a primary target outside the CNS. For all other drugs, domain-specific cognitive screening tools should be used. They should be selected according to the study population as well as the condition and drug studied. Examples for appropriate tools include EpiTrack[®], the Rowland Universal Dementia Assessment Scale (RUDAS), or the Mini-Cog[®].

Apart from active assessment of cognitive safety in drug trials, raised awareness of DICI among health care professionals is a necessity. DICI should become a regular differential diagnosis in all kinds of cognitive impairment in patients receiving drug treatment.

Declarations

Funding Open access funding provided by Lund University.

Conflicts of Interest The authors declare no conflicts of interest.

Ethics Approval Not applicable.

Consent to Participate Not applicable.

Consent for Publication Not applicable.

Availability of Data and Materials Not applicable.

Code Availability Not applicable.

Author Contributions Arne Reimers: conceptualisation, methodology, investigation, writing—original draft, writing—review and editing. Per Odin: writing—review and editing. Hanna Ljung: conceptualisation, methodology, writing—review and editing, supervision. All authors have read and agreed to the submitted version of the manuscript.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

References

1. Meador KJ. Cognitive side effects of medications. *Neurol Clin North Am.* 1998;16(1):141–55.
2. Hafez G, Malyszko J, Golenia A, Klimkowicz-Mrowiec A, Ferreira AC, Arici M, et al. Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients. *Clin Kidney J.* 2023;16(12):2378–92. <https://doi.org/10.1093/cjk/sfad239>.
3. Prendergast NT, Tiberio PJ, Girard TD. Treatment of delirium during critical illness. *Annu Rev Med.* 2022;73:407–21. <https://doi.org/10.1146/annurev-med-042220-013015>.
4. Stoner SC. Drug-induced cognitive dysfunction. *Med Update Psychiatrists.* 1997;2(3):81–5. [https://doi.org/10.1016/S1082-7579\(97\)00004-6](https://doi.org/10.1016/S1082-7579(97)00004-6).
5. Clarfield AM. The reversible dementias: do they reverse? *Ann Intern Med.* 1988;109(6):476–86. <https://doi.org/10.7326/0003-4819-109-6-476>.
6. Orszaghova Z, Mego M, Chovanec M. Long-term cognitive dysfunction in cancer survivors. *Front Mol Biosci.* 2021;8:770413. <https://doi.org/10.3389/fmolb.2021.770413>.
7. First MB, American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5-TR. Fifth edition, text revision ed. Washington: American Psychiatric Association Publishing; 2022.
8. Larson EB, Reifler BV, Sumi SM, Canfield CG, Chinn NM. Features of potentially reversible dementia in elderly outpatients. *West J Med.* 1986;145(4):488–92.
9. Alpert JS. Polypharmacy in elderly patients: the march goes on and on. *Am J Med.* 2017;130(8):875–6. <https://doi.org/10.1016/j.amjmed.2017.03.012>.
10. National Center for Health Statistics. National Health and Nutrition Examination Survey: Prescription drug use in the past 30 days, by sex, race and Hispanic origin, and age: United States, selected years 1988–1994 through 2015–2018—Con. Available from: <https://www.cdc.gov/nchs/data/hus/2019/039-508.pdf>. Accessed Dec 3, 2024
11. Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. *Ann Intern Med.* 1987;107(2):169–73. <https://doi.org/10.7326/0003-4819-107-2-169>.
12. Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. *Expert Opin Drug Saf.* 2018;17(12):1185–96. <https://doi.org/10.1080/14740338.2018.1546841>.
13. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. *BMC Med.* 2015;13:74. <https://doi.org/10.1186/s12916-015-0322-7>.
14. Delara M, Murray L, Jafari B, Bahji A, Goodarzi Z, Kirkham J, et al. Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis. *BMC Geriatr.* 2022;22(1):601. <https://doi.org/10.1186/s12877-022-03279-x>.
15. Dautzenberg L, Jessurum N, Dautzenberg PL, Keijsers CJ. Reversible methotrexate-induced dementia: a case report. *J Am Geriatr Soc.* 2015;63(6):1273–4. <https://doi.org/10.1111/jgs.13517>.
16. Kurlan R, Como P. Drug-induced alzheimerism. *Arch Neurol.* 1988;45(3):356–7. <https://doi.org/10.1001/archneur.1988.00520270138035>.
17. Slegers MJ, Beutler JJ, Hardon WJ, Berden JH, Verhave JC, Conemans JM, et al. Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus. *J Am Geriatr Soc.* 2010;58(4):799–801. <https://doi.org/10.1111/j.1532-5415.2010.02795.x>.
18. Lindbom U, Taubert B, Fahlqvist MS, Bergens A, Kimland E, Jonsson EW, et al. Reversible dementia-like condition and parkinsonism in an elderly woman. Idiosyncratic adverse effects connected to 11 years of antiepileptic medication. *Lakartidnngen.* 2009;106(12):863–5.
19. Sacks O, Shulman M. Steroid dementia: an overlooked diagnosis? *Neurology.* 2005;64(4):707–9. <https://doi.org/10.1212/01.WNL.0000151977.18440.C3>.
20. Howard R, Schott JM. When dementia is misdiagnosed. *Int J Geriatr Psychiatry.* 2021;36(6):799–801. <https://doi.org/10.1002/gps.5538>.
21. Han JH, Wilson A, Ely EW. Delirium in the older emergency department patient: a quiet epidemic. *Emerg Med Clin North Am.* 2010;28(3):611–31. <https://doi.org/10.1016/j.emc.2010.03.005>.
22. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. *Drugs Aging.* 1999;15(1):15–28. <https://doi.org/10.2165/00002512-199915010-00002>.
23. Hein C, Forgues A, Piau A, Sommet A, Vellas B, Nourhashemi F. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. *J Am Med Dir Assoc.* 2014;15(11):850. <https://doi.org/10.1016/j.jamda.2014.08.012>. (e11–5).
24. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. *JAMA.* 2014;312(23):2551–61. <https://doi.org/10.1001/jama.2014.13806>.
25. Cao Q, Tan CC, Xu W, Hu H, Cao XP, Dong Q, et al. The prevalence of dementia: a systematic review and meta-analysis. *J Alzheimers Dis.* 2020;73(3):1157–66. <https://doi.org/10.3233/JAD-191092>.
26. Collaborators GBDDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health.* 2022;7(2):e105–25. [https://doi.org/10.1016/S2468-2667\(21\)00249-8](https://doi.org/10.1016/S2468-2667(21)00249-8).
27. Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. *J Neurol Neurosurg Psychiatry.* 2015;86(12):1299–306. <https://doi.org/10.1136/jnnp-2015-310548>.
28. WHO. Dementia. Available from: <https://www.who.int/news-room/fact-sheets/detail/dementia>. Accessed Dec 3, 2024
29. Alzheimer's Disease International. Risk factors and risk reduction. Available from: <https://www.alzint.org/about/risk-factors-risk-reduction/>. Accessed Dec 3, 2024
30. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet.* 2020;396(10248):413–46. [https://doi.org/10.1016/S0140-6736\(20\)30367-6](https://doi.org/10.1016/S0140-6736(20)30367-6).

31. Apostolo J, Holland C, O'Connell MD, Feeney J, Tabares-Seisdedos R, Tados G, et al. Mild cognitive decline A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAH). *Maturitas*. 2016;83:83–93. <https://doi.org/10.1016/j.maturitas.2015.10.008>.
32. Roebuck-Spencer TM, Glen T, Puente AE, Denney RL, Ruff RM, Hostetter G, et al. Cognitive screening tests versus comprehensive neuropsychological test batteries: a national academy of neuropsychology education paperdagger. *Arch Clin Neuropsychol*. 2017;32(4):491–8. <https://doi.org/10.1093/arclin/acx021>.
33. Herreen D, Zajac IT. The reliability and validity of a self-report measure of cognitive abilities in older adults: more personality than cognitive function. *J Intell*. 2017. <https://doi.org/10.3390/jintelligence6010001>.
34. Weinstein AM, Gujral S, Butters MA, Bowie CR, Fischer CE, Flint AJ, et al. Diagnostic precision in the detection of mild cognitive impairment: a comparison of two approaches. *Am J Geriatr Psychiatry*. 2022;30(1):54–64. <https://doi.org/10.1016/j.jagp.2021.04.004>.
35. Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, et al. Parkinson disease-associated cognitive impairment. *Nat Rev Dis Primers*. 2021;7(1):47. <https://doi.org/10.1038/s41572-021-00280-3>.
36. Sjogren P, Christrup LL, Petersen MA, Hojsted J. Neuropsychological assessment of chronic non-malignant pain patients treated in a multidisciplinary pain centre. *Eur J Pain*. 2005;9(4):453–62. <https://doi.org/10.1016/j.ejpain.2004.10.005>.
37. Chan E, Khan S, Oliver R, Gill SK, Werring DJ, Cipolotti L. Underestimation of cognitive impairments by the Montreal Cognitive Assessment (MoCA) in an acute stroke unit population. *J Neurol Sci*. 2014;343(1–2):176–9. <https://doi.org/10.1016/j.jns.2014.05.005>.
38. Olson RA, Iverson GL, Carolan H, Parkinson M, Brooks BL, McKenzie M. Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life. *J Neurooncol*. 2011;105(2):337–44. <https://doi.org/10.1007/s11060-011-0595-4>.
39. Reimers A, Ljung H. Cognitive safety is largely ignored in clinical drug trials: a study of registered study protocols. *Drug Saf*. 2024;47(1):23–8. <https://doi.org/10.1007/s40264-023-01378-1>.
40. Dugard A, Giraudeau B, Dibao-Dina C. Do patients with type 2 diabetes mellitus included in randomised clinical trials differ from general-practice patients? A cross-sectional comparative study. *BMJ Open*. 2024;14(4):e077582. <https://doi.org/10.1136/bmjopen-2023-077582>.
41. Jacobson TA. NLA task force on statin safety–2014 update. *J Clin Lipidol*. 2014;8(3 Suppl):S1–4. <https://doi.org/10.1016/j.jacl.2014.03.003>.
42. Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs. *Epilepsy Behav*. 2004;5(Suppl 1):S60–5. <https://doi.org/10.1016/j.yebeh.2003.11.008>.
43. Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. *Epilepsy Res*. 2006;68(1):63–7. <https://doi.org/10.1016/j.eplepsyres.2005.09.023>.
44. Park SP, Kwon SH. Cognitive effects of antiepileptic drugs. *J Clin Neurol*. 2008;4(3):99–106. <https://doi.org/10.3988/jcn.2008.4.3.99>.
45. Besag FMC, Vasey MJ. Neurocognitive effects of antiepileptic medications in children and adolescents with epilepsy. *Paediatr Drugs*. 2021;23(3):253–86. <https://doi.org/10.1007/s40272-021-00448-0>.
46. Hermann B, Meador KJ, Gaillard WD, Cramer JA. Cognition across the lifespan: antiepileptic drugs, epilepsy, or both? *Epilepsy Behav*. 2010;17(1):1–5. <https://doi.org/10.1016/j.yebeh.2009.10.019>.
47. Marino SE, Pakhomov SV, Han S, Anderson KL, Ding M, Eberly LE, et al. The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory. *Epilepsy Behav*. 2012;24(3):365–72. <https://doi.org/10.1016/j.yebeh.2012.04.120>.
48. Reimers A, Ljung H. An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy. *Expert Opin Pharmacother*. 2019;20(8):909–15. <https://doi.org/10.1080/14656566.2019.1595584>.
49. Battaglia D, Iuvone L, Stefanini MC, Acquafondata C, Lettori D, Chiricozzi F, et al. Reversible aphasic disorder induced by lamotrigine in atypical benign childhood epilepsy. *Epileptic Disord*. 2001;3(4):217–22.
50. Brown JC, Broadway JL. Lamotrigine-associated progressive dysphasia and cognitive dysfunction. *OBM Neurobiol*. 2021. <https://doi.org/10.21926/obm.neurobiol.2102091>.
51. Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. *Behav Neurol*. 2018;2018:2064027. <https://doi.org/10.1155/2018/2064027>.
52. Reimers A. Antiepileptic drugs. In: Offermanns S, Rosenthal W, editors. *Encyclopedia of molecular pharmacology*. Cham: Springer International Publishing; 2020. p. 1–19.
53. Loscher W, Klein P. The pharmacology and clinical efficacy of antiepileptic medications: from bromide salts to cenobamate and beyond. *CNS Drugs*. 2021;35(9):935–63. <https://doi.org/10.1007/s40263-021-00827-8>.
54. Wirrell E, Sherman EM, Vanmastrigt R, Hamiwka L. Deterioration in cognitive function in children with benign epilepsy of childhood with central temporal spikes treated with sulthiame. *J Child Neurol*. 2008;23(1):14–21. <https://doi.org/10.1177/0883073807307082>.
55. Ramey P, Osborn M, Kirshner H, Abou-Khalil B. Misdiagnosis of lamotrigine toxicity as posterior circulation transient ischemic attack or stroke. *Epilepsy Behav*. 2020;111: 107284. <https://doi.org/10.1016/j.yebeh.2020.107284>.
56. Westercamp NS, Sharma A. Case report: lamotrigine toxicity leading to depressed mental activity. *Prim Care Companion CNS Disord*. 2012. <https://doi.org/10.4088/PCC.11101278>.
57. Witt JA, Widman G, Hansen N, von Wrede R, Elger CE, Helmstaedter C. Evaluation of a rapid topiramate titration scheme for the early detection of cognitive side effects. *CNS Drugs*. 2022;36(12):1325–30. <https://doi.org/10.1007/s40263-022-00969-3>.
58. Hesar K, Luck T, Rohr S, Wiese B, Kaduszkiewicz H, Oey A, et al. Potentially inappropriate medication: association between the use of antidepressant drugs and the subsequent risk for dementia. *J Affect Disord*. 2018;226:28–35. <https://doi.org/10.1016/j.jad.2017.09.016>.
59. Lee CW, Lin CL, Sung FC, Liang JA, Kao CH. Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study. *J Clin Psychiatry*. 2016;77(1):117–22. <https://doi.org/10.4088/JCP.14m09580>. (quiz 22).
60. Kodesh A, Sandin S, Reichenberg A, Rotstein A, Pedersen NL, Ericsson M, et al. Exposure to antidepressant medication and the risk of incident dementia. *Am J Geriatr Psychiatry*. 2019;27(11):1177–88. <https://doi.org/10.1016/j.jagp.2019.05.019>.
61. Brender R, Mulsant BH, Blumberger DM. An update on antidepressant pharmacotherapy in late-life depression. *Expert Opin Pharmacother*. 2021;22(14):1909–17. <https://doi.org/10.1080/14656566.2021.1921736>.
62. Qian H, Shu C, Xiao L, Wang G. Histamine and histamine receptors: Roles in major depressive disorder. *Front Psychiatry*. 2022;13: 825591. <https://doi.org/10.3389/fpsy.2022.825591>.

63. Alvarez EO. The role of histamine on cognition. *Behav Brain Res.* 2009;199(2):183–9. <https://doi.org/10.1016/j.bbr.2008.12.010>.
64. American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. *J Am Geriatr Soc.* 2023;71(7):2052–81. <https://doi.org/10.1111/jgs.18372>.
65. Levkovitz Y, Caftori R, Avital A, Richter-Levin G. The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. *Brain Res Bull.* 2002;58(4):345–50. [https://doi.org/10.1016/s0361-9230\(01\)00780-8](https://doi.org/10.1016/s0361-9230(01)00780-8).
66. Culang-Reinlieb ME, Sneed JR, Keilp JG, Roose SP. Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. *Int J Geriatr Psychiatry.* 2012;27(8):777–84. <https://doi.org/10.1002/gps.2783>.
67. Sayyah M, Eslami K, AlaiShehni S, Kouti L. Cognitive function before and during treatment with selective serotonin reuptake inhibitors in patients with depression or obsessive-compulsive disorder. *Psychiatry J.* 2016;2016:5480391. <https://doi.org/10.1155/2016/5480391>.
68. Chakrabarty T, Hadjipavlou G, Lam RW. Cognitive dysfunction in major depressive disorder: assessment, impact, and management. *Focus (Am Psychiatr Publ).* 2016;14(2):194–206. <https://doi.org/10.1176/appi.focus.20150043>.
69. James TA, Weiss-Cowie S, Hopton Z, Verhaeghen P, Dotson VM, Duarte A. Depression and episodic memory across the adult lifespan: a meta-analytic review. *Psychol Bull.* 2021;147(11):1184–214. <https://doi.org/10.1037/bul0000344>.
70. Popovic D, Vieta E, Fornaro M, Perugi G. Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRI antidepressants. *J Affect Disord.* 2015;173:211–5. <https://doi.org/10.1016/j.jad.2014.11.008>.
71. Wadsworth EJ, Moss SC, Simpson SA, Smith AP. SSRIs and cognitive performance in a working sample. *Hum Psychopharmacol.* 2005;20(8):561–72. <https://doi.org/10.1002/hup.725>.
72. Serretti A, Calati R, Goracci A, Di Simplicio M, Castrogiovanni P, De Ronchi D. Antidepressants in healthy subjects: what are the psychotropic/psychological effects? *Eur Neuropsychopharmacol.* 2010;20(7):433–53. <https://doi.org/10.1016/j.euroneuro.2009.11.009>.
73. Leth-Moller KB, Hansen AH, Torstensson M, Andersen SE, Odum L, Gislason G, et al. Antidepressants and the risk of hyponatremia: a Danish register-based population study. *BMJ Open.* 2016;6(5): e011200. <https://doi.org/10.1136/bmjopen-2016-011200>.
74. Mannesse CK, Jansen PA, Van Marum RJ, Sival RC, Kok RM, Haffmans PM, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. *Maturitas.* 2013;76(4):357–63. <https://doi.org/10.1016/j.maturitas.2013.08.010>.
75. Zieschang T, Wolf M, Vellappallil T, Uhlmann L, Oster P, Kopf D. The association of hyponatremia, risk of confusional state, and mortality. *Dtsch Arztebl Int.* 2016;113(50):855–62. <https://doi.org/10.3238/arztebl.2016.0855>.
76. Fujishiro J, Imanishi T, Onozawa K, Tsushima M. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. *Eur J Pharmacol.* 2002;454(2–3):183–8. [https://doi.org/10.1016/s0014-2999\(02\)02557-8](https://doi.org/10.1016/s0014-2999(02)02557-8).
77. Ellison JM. A 60-year-old woman with mild memory impairment: review of mild cognitive impairment. *JAMA.* 2008;300(13):1566–74. <https://doi.org/10.1001/jama.300.9.jrr80008>.
78. Herzallah MM, Moustafa AA, Natsheh JY, Danoun OA, Simon JR, Tayem YI, et al. Depression impairs learning, whereas the selective serotonin reuptake inhibitor, paroxetine, impairs generalization in patients with major depressive disorder. *J Affect Disord.* 2013;151(2):484–92. <https://doi.org/10.1016/j.jad.2013.06.030>.
79. Nowak JZ, Arrang JM, Schwartz JC, Garbarg M. Interaction between mianserin, an antidepressant drug, and central H1- and H2-histamine-receptors: in vitro and in vivo studies and radioreceptor assay. *Neuropharmacology.* 1983;22(3):259–66. [https://doi.org/10.1016/0028-3908\(83\)90238-1](https://doi.org/10.1016/0028-3908(83)90238-1).
80. Schwasinger-Schmidt TE, Macaluso M. Other antidepressants. *Handb Exp Pharmacol.* 2019;250:325–55. https://doi.org/10.1007/164_2018_167.
81. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. *CNS Drugs.* 2010;24(1):35–53. <https://doi.org/10.2165/11319480-000000000-00000>.
82. Curran HV, Lader M. The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects. *Eur J Clin Pharmacol.* 1986;29(5):601–7. <https://doi.org/10.1007/BF00635900>.
83. Sasada K, Iwamoto K, Kawano N, Kohmura K, Yamamoto M, Aleksic B, et al. Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers. *Hum Psychopharmacol.* 2013;28(3):281–6. <https://doi.org/10.1002/hup.2321>.
84. Wingen M, Bothmer J, Langer S, Ramaekers JG. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. *J Clin Psychiatry.* 2005;66(4):436–43. <https://doi.org/10.4088/jcp.v66n0405>.
85. Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. *Pharmacol Biochem Behav.* 2011;99(2):211–6. <https://doi.org/10.1016/j.pbb.2011.01.020>.
86. Jhanda S, Singla N, Grover S. Methylphenidate-induced obsessive-compulsive symptoms: a case report and review of literature. *J Pediatr Neurosci.* 2016;11(4):316–8. <https://doi.org/10.4103/1817-1745.199461>.
87. Jacobsen LK, Chappell P, Woolston JL. Bupropion and compulsive behavior. *J Am Acad Child Adolesc Psychiatry.* 1994;33(1):143–4. <https://doi.org/10.1097/00004583-199401000-00023>.
88. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. *Neuropsychopharmacology.* 1993;8(1):23–33. <https://doi.org/10.1038/npp.1993.4>.
89. Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. *Am J Hosp Pharm.* 1994;51(24):3033–46.
90. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. *CMAJ.* 1996;155(5):519–27.
91. Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. *Int J Geriatr Psychiatry.* 1998;13(1):12–5.
92. Bishara D. Managing drugs with anticholinergic activity. *Drug Ther Bull.* 2023;61(9):135–9. <https://doi.org/10.1136/dtb.2022.000066>.

93. Fallon SJ, Smulders K, Esselink RA, van de Warrenburg BP, Bloem BR, Cools R. Differential optimal dopamine levels for set-shifting and working memory in Parkinson's disease. *Neuropsychologia*. 2015;77:42–51. <https://doi.org/10.1016/j.neuropsychologia.2015.07.031>.
94. Breitenstein C, Korsukewitz C, Floel A, Kretschmar T, Diederich K, Knecht S. Tonic dopaminergic stimulation impairs associative learning in healthy subjects. *Neuropsychopharmacology*. 2006;31(11):2552–64. <https://doi.org/10.1038/sj.npp.1301167>.
95. Pizzagalli DA, Evins AE, Schetter EC, Frank MJ, Pajtas PE, Santesso DL, et al. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. *Psychopharmacology*. 2008;196(2):221–32. <https://doi.org/10.1007/s00213-007-0957-y>.
96. Frank MJ, O'Reilly RC. A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol. *Behav Neurosci*. 2006;120(3):497–517. <https://doi.org/10.1037/0735-7044.120.3.497>.
97. Santesso DL, Evins AE, Frank MJ, Schetter EC, Bogdan R, Pizzagalli DA. Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function. *Hum Brain Mapp*. 2009;30(7):1963–76. <https://doi.org/10.1002/hbm.20642>.
98. Jahanshahi M, Wilkinson L, Gahir H, Dharmaindra A, Lagnado DA. Medication impairs probabilistic classification learning in Parkinson's disease. *Neuropsychologia*. 2010;48(4):1096–103. <https://doi.org/10.1016/j.neuropsychologia.2009.12.010>.
99. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. *J Am Geriatr Soc*. 1991;39(7):708–16. <https://doi.org/10.1111/j.1532-5415.1991.tb03627.x>.
100. El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. *J Clin Pharm Ther*. 2016;41(1):7–18. <https://doi.org/10.1111/jcpt.12357>.
101. Dal Santo F, Jarratt-Barnham I, Gonzalez-Blanco L, Garcia-Portilla MP, Bobes J, Fernandez-Egea E. Longitudinal effects of clozapine concentration and clozapine to *N*-desmethylclozapine ratio on cognition: a mediation model. *Eur Neuropsychopharmacol*. 2020;33:158–63. <https://doi.org/10.1016/j.euroneuro.2020.01.016>.
102. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. *J Clin Psychiatry*. 2002;63(Suppl 13):5–11.
103. Mukku SSR, Sivakumar PT, Varghese M. Clozapine use in geriatric patients—challenges. *Asian J Psychiatr*. 2018;33:63–7. <https://doi.org/10.1016/j.ajp.2018.03.008>.
104. Ballesteros A, Sanchez-Torres AM, Lopez-Ilundain JM, Cabrera B, Lobo A, Gonzalez-Pinto AM, et al. Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis? *Psychol Med*. 2018;48(13):2247–56. <https://doi.org/10.1017/S0033291717003774>.
105. Humbert-Claude M, Davenas E, Gbahou F, Vincent L, Arrang JM. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. *Psychopharmacology*. 2012;220(1):225–41. <https://doi.org/10.1007/s00213-011-2471-5>.
106. Friedman JH. Parkinson's disease psychosis management: an evidence based, experience informed, pragmatic approach. *Expert Opin Pharmacother*. 2024;25(2):149–56. <https://doi.org/10.1080/14656566.2024.2316135>.
107. Sheffield JM, Karcher NR, Barch DM. Cognitive deficits in psychotic disorders: a lifespan perspective. *Neuropsychol Rev*. 2018;28(4):509–33. <https://doi.org/10.1007/s11065-018-9388-2>.
108. Elie D, Poirier M, Chianetta J, Durand M, Gregoire C, Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. *J Psychopharmacol*. 2010;24(7):1037–44. <https://doi.org/10.1177/0269881108100777>.
109. Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, et al. Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. *Pharmacol Ther*. 2018;192:20–41. <https://doi.org/10.1016/j.pharmthera.2018.06.012>.
110. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. *Expert Rev Neurother*. 2010;10(1):43–57. <https://doi.org/10.1586/ern.09.143>.
111. Stahl SM. Stahl's essential psychopharmacology : neuroscientific basis and practical application. 4th ed. Cambridge: Cambridge University Press; 2013.
112. Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D. Influence of antipsychotic and anticholinergic loads on cognitive functions in patients with schizophrenia. *Schizophr Res Treatment*. 2016;2016:8213165. <https://doi.org/10.1155/2016/8213165>.
113. MacKintosh D. Olanzapine induced delirium—a “probable” adverse drug reaction. *Ann Palliat Med*. 2017;6(Suppl 1):S257–9. <https://doi.org/10.21037/apm.2017.06.04>.
114. Samuels S, Fang M. Olanzapine may cause delirium in geriatric patients. *J Clin Psychiatry*. 2004;65(4):582–3.
115. Sharma RC, Aggarwal A. Delirium associated with olanzapine therapy in an elderly male with bipolar affective disorder. *Psychiatry Investig*. 2010;7(2):153–4. <https://doi.org/10.4306/pi.2010.7.2.153>.
116. Cortes-Flores H, Torrandell-Haro G, Brinton RD. Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseases. *Front Psychiatry*. 2024;15:1358568. <https://doi.org/10.3389/fpsy.2024.1358568>.
117. Guo X, Zhang Z, Wei Q, Lv H, Wu R, Zhao J. The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. *BMC Psychiatry*. 2013;13:109. <https://doi.org/10.1186/1471-244X-13-109>.
118. Sui SX, Pasco JA. Obesity and brain function: the brain-body crosstalk. *Medicina (Kaunas)*. 2020. <https://doi.org/10.3390/medicina56100499>.
119. Voineskos AN, Mulsant BH, Dickie EW, Neufeld NH, Rothchild AJ, Whyte EM, et al. Effects of antipsychotic medication on brain structure in patients with major depressive disorder and psychotic features: neuroimaging findings in the context of a randomized placebo-controlled clinical trial. *JAMA Psychiat*. 2020;77(7):674–83. <https://doi.org/10.1001/jamapsychiatry.2020.0036>.
120. Lesh TA, Tanase C, Geib BR, Niendam TA, Yoon JH, Minzenberg MJ, et al. A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. *JAMA Psychiat*. 2015;72(3):226–34. <https://doi.org/10.1001/jamapsychiatry.2014.2178>.
121. Gjerde PB, Jorgensen KN, Steen NE, Melle I, Andreassen OA, Steen VM, et al. Association between olanzapine treatment and brain cortical thickness and gray/white matter contrast is moderated by cholesterol in psychotic disorders. *Psychiatry Res Neuroimaging*. 2018;282:55–63. <https://doi.org/10.1016/j.psychres.2018.10.001>.
122. van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, et al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) consortium. *Biol Psychiatry*. 2018;84(9):644–54. <https://doi.org/10.1016/j.biopsych.2018.04.023>.

123. Liu N, Xiao Y, Zhang W, Tang B, Zeng J, Hu N, et al. Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients. *Transl Psychiatry*. 2020;10(1):136. <https://doi.org/10.1038/s41398-020-0828-4>.
124. Chen Y, Womer FY, Feng R, Zhang X, Zhang Y, Duan J, et al. A real-world observation of antipsychotic effects on brain volumes and intrinsic brain activity in schizophrenia. *Front Neurosci*. 2021;15: 749316. <https://doi.org/10.3389/fnins.2021.749316>.
125. Zong X, Wang G, Nie Z, Ma S, Kang L, Zhang N, et al. Longitudinal multi-omics alterations response to 8-week risperidone monotherapy: evidence linking cortical thickness, transcriptomics and epigenetics. *Front Psychiatry*. 2023;14:1127353. <https://doi.org/10.3389/fpsyt.2023.1127353>.
126. van Haren NE, Schnack HG, Cahn W, van den Heuvel MP, Lepage C, Collins L, et al. Changes in cortical thickness during the course of illness in schizophrenia. *Arch Gen Psychiatry*. 2011;68(9):871–80. <https://doi.org/10.1001/archgenpsychiatry.2011.88>.
127. Bortolozzi A, Fico G, Berk M, Solmi M, Fornaro M, Quevedo J, et al. New advances in the pharmacology and toxicology of lithium: a neurobiologically oriented overview. *Pharmacol Rev*. 2024;76(3):323–57. <https://doi.org/10.1124/pharmrev.120.000007>.
128. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. *Lancet*. 2012;379(9817):721–8. [https://doi.org/10.1016/S0140-6736\(11\)61516-X](https://doi.org/10.1016/S0140-6736(11)61516-X).
129. Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: a meta-analysis. *J Clin Psychiatry*. 2009;70(11):1588–97. <https://doi.org/10.4088/JCP.08r04972>.
130. Kronk NN, Kronk BK, Robbie AT. A case report: lithium-induced neurotoxicity, a differential to always consider. *Cureus*. 2023;15(12): e50225. <https://doi.org/10.7759/cureus.50225>.
131. Carmassi C, Nardi B, Battaglini S, Bonelli C, Violi M, Bonanni E, et al. A case of lithium encephalopathy with therapeutic lithium levels: the diagnostic role of EEG. *Case Rep Psychiatry*. 2022;2022:8052471. <https://doi.org/10.1155/2022/8052471>.
132. Evrensel A, Unsalver BO, Ceylan ME, Comert G. Lithium-induced cortical atrophy and cognitive dysfunction. *BMJ Case Rep*. 2014. <https://doi.org/10.1136/bcr-2014-207646>.
133. Hay G, Simpson N. Neurotoxicity associated with therapeutic serum lithium levels. *Lancet*. 1982;2(8290):160–1. [https://doi.org/10.1016/s0140-6736\(82\)91130-8](https://doi.org/10.1016/s0140-6736(82)91130-8).
134. Soriano-Barcelo J, Alonso MT, Traba MB, Vilar AA, Kahn DA. A case with reversible neurotoxicity after 2 years of dementia secondary to maintenance lithium treatment. *J Psychiatr Pract*. 2015;21(2):154–9. <https://doi.org/10.1097/01.pra.0000462608.02478.16>.
135. Gallinat J, Boetsch T, Padberg F, Hampel H, Herrmann WM, Hegerl U. Is the EEG helpful in diagnosing and monitoring lithium intoxication? A case report and review of the literature. *Pharmacopsychiatry*. 2000;33(5):169–73.
136. Valtonen J, Karrasch M. Polypharmacy-induced cognitive dysfunction and discontinuation of psychotropic medication: a neuropsychological case report. *Ther Adv Psychopharmacol*. 2020;10:2045125320905734. <https://doi.org/10.1177/2045125320905734>.
137. Greenblatt DJ. Pharmacology of benzodiazepine hypnotics. *J Clin Psychiatry*. 1992;53(Suppl):7–13.
138. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. *Drug Saf*. 2003;26(4):261–82. <https://doi.org/10.2165/00002018-200326040-00004>.
139. Wolkowitz OM, Weingartner H, Thompson K, Pickar D, Paul SM, Hommer DW. Diazepam-induced amnesia: a neuropharmacological model of an “organic amnesic syndrome.” *Am J Psychiatry*. 1987;144(1):25–9. <https://doi.org/10.1176/ajp.144.1.25>.
140. O’Boyle CA. Benzodiazepine-induced amnesia and anaesthetic practice: a review. *Psychopharmacol Ser*. 1988;6:146–65.
141. Stewart SA. The effects of benzodiazepines on cognition. *J Clin Psychiatry*. 2005;66(Suppl 2):9–13.
142. Hanlon JT, Horner RD, Schmader KE, Fillenbaum GG, Lewis IK, Wall WE Jr, et al. Benzodiazepine use and cognitive function among community-dwelling elderly. *Clin Pharmacol Ther*. 1998;64(6):684–92. [https://doi.org/10.1016/S0009-9236\(98\)90059-5](https://doi.org/10.1016/S0009-9236(98)90059-5).
143. Liu L, Jian P, Zhou Y, Zhou J, Jia L, Tang M, et al. Is the long-term use of benzodiazepines associated with worse cognition performance in highly educated older adults? *Front Psychiatry*. 2020;11: 595623. <https://doi.org/10.3389/fpsyt.2020.595623>.
144. Kurlawala Z, Roberts JA, McMillan JD, Friedland RP. Diazepam toxicity presenting as a dementia disorder. *J Alzheimers Dis*. 2018;66(3):935–8. <https://doi.org/10.3233/JAD-180745>.
145. Bierman EJ, Comijs HC, Gundy CM, Sonnenberg C, Jonker C, Beekman AT. The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? *Int J Geriatr Psychiatry*. 2007;22(12):1194–200. <https://doi.org/10.1002/gps.1811>.
146. Ferreira P, Ferreira AR, Barreto B, Fernandes L. Is there a link between the use of benzodiazepines and related drugs and dementia? A systematic review of reviews. *Eur Geriatr Med*. 2022;13(1):19–32. <https://doi.org/10.1007/s41999-021-00553-w>.
147. Duprey MS, Devlin JW, Griffith JL, Trivison TG, Briesacher BA, Jones R, et al. Association between perioperative medication use and postoperative delirium and cognition in older adults undergoing elective noncardiac surgery. *Anesth Analg*. 2022;134(6):1154–63. <https://doi.org/10.1213/ANE.0000000000005959>.
148. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnotics: zaleplon, zolpidem and zopiclone. *Clin Pharmacokinet*. 2004;43(4):227–38. <https://doi.org/10.2165/00003088-200443040-00002>.
149. Warner NS, Mielke MM, Verdoorn BP, Knopman DS, Hooten WM, Habermann EB, et al. Pain, opioid analgesics, and cognition: a conceptual framework in older adults. *Pain Med*. 2023;24(2):171–81. <https://doi.org/10.1093/pm/pnac113>.
150. Strassels SA. Cognitive effects of opioids. *Curr Pain Headache Rep*. 2008;12(1):32–6. <https://doi.org/10.1007/s11916-008-0007-4>.
151. Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. *J Pain Palliat Care Pharmacother*. 2007;21(1):15–25.
152. Strand MC, Fjeld B, Arnestad M, Morland J. Can patients receiving opioid maintenance therapy safely drive? A systematic review of epidemiological and experimental studies on driving ability with a focus on concomitant methadone or buprenorphine administration. *Traffic Inj Prev*. 2013;14(1):26–38. <https://doi.org/10.1080/15389588.2012.689451>.
153. Ito G, Kanemoto K. A case of topical opioid-induced delirium mistaken as behavioural and psychological symptoms of dementia in demented state. *Psychogeriatrics*. 2013;13(2):118–23. <https://doi.org/10.1111/psyg.12007>.
154. Butenschoen VM, Wriedt F, Meyer B, Krieg SM. Neurocognitive monitoring in patients undergoing opioid pain medication after spinal surgery: a feasibility study of a new monitoring method. *Acta Neurochir (Wien)*. 2023;165(2):335–40. <https://doi.org/10.1007/s00701-023-05486-w>.

155. Kowalski-McGraw M, Green-McKenzie J, Pandalai SP, Schulte PA. Characterizing the interrelationships of prescription opioid and benzodiazepine drugs with worker health and workplace hazards. *J Occup Environ Med*. 2017;59(11):1114–26. <https://doi.org/10.1097/JOM.0000000000001154>.
156. Barash JA, Whitley J, Watson CJ, Boyle K, Lim C, Lev MH, et al. Opioid-associated amnestic syndrome: description of the syndrome and validation of a proposed definition. *J Neurol Sci*. 2020;417: 117048. <https://doi.org/10.1016/j.jns.2020.117048>.
157. Walker ML, Patel K, Li T, Kassir M. Opioid-associated amnestic syndrome. *Cureus*. 2021;13(11): e20056. <https://doi.org/10.7759/cureus.20056>.
158. McConnell E, Bai J. Hippocampal and cerebellar involvement in opioid-associated amnestic syndrome: a unique case report. *Cureus*. 2023;15(8): e44248. <https://doi.org/10.7759/cureus.44248>.
159. Grudt TJ, Williams JT. Opioid receptors and the regulation of ion conductances. *Rev Neurosci*. 1995;6(3):279–86. <https://doi.org/10.1515/revneuro.1995.6.3.279>.
160. Zollner C, Stein C. Opioids. *Handb Exp Pharmacol*. 2007;177:31–63. https://doi.org/10.1007/978-3-540-33823-9_2.
161. Shiga Y, Minami K, Shiraishi M, Uezono Y, Murasaki O, Kaibara M, et al. The inhibitory effects of tramadol on muscarinic receptor-induced responses in *Xenopus* oocytes expressing cloned M(3) receptors. *Anesth Analg*. 2002;95(5):1269–73. <https://doi.org/10.1097/0000539-200211000-00031>.
162. Hassaan SH, Khalifa H, Darwish AM. Effects of extended abstinence on cognitive functions in tramadol-dependent patients: a cohort study. *Neuropsychopharmacol Rep*. 2021;41(3):371–8. <https://doi.org/10.1002/npr.2.12188>.
163. Bortolotto V, Grilli M. Opiate analgesics as negative modulators of adult hippocampal neurogenesis: potential implications in clinical practice. *Front Pharmacol*. 2017;8:254. <https://doi.org/10.3389/fphar.2017.00254>.
164. Mao J, Sung B, Ji RR, Lim G. Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. *J Neurosci*. 2002;22(17):7650–61. <https://doi.org/10.1523/JNEUROSCI.22-17-07650.2002>.
165. Oh TK, Song IA. Impact of prescribed opioid use on development of dementia among patients with chronic non-cancer pain. *Sci Rep*. 2024;14(1):3313. <https://doi.org/10.1038/s41598-024-53728-3>.
166. Levine SZ, Rotstein A, Goldberg Y, Reichenberg A, Kodesh A. Opioid exposure and the risk of dementia: a national cohort study. *Am J Geriatr Psychiatry*. 2023;31(5):315–23. <https://doi.org/10.1016/j.jagp.2022.05.013>.
167. Jain G, Mahendra V, Singhal S, Dzara K, Pilla TR, Manworren R, et al. Long-term neuropsychological effects of opioid use in children: a descriptive literature review. *Pain Physician*. 2014;17(2):109–18.
168. Gao Y, Su B, Ding L, Qureshi D, Hong S, Wei J, et al. Association of regular opioid use with incident dementia and neuroimaging markers of brain health in chronic pain patients: analysis of UK biobank. *Am J Geriatr Psychiatry*. 2024. <https://doi.org/10.1016/j.jagp.2024.04.010>.
169. Jensen-Dahm C, Janbek J, Gasse C, Munk Laurssen T, Waldemar G. Excessive mortality risk associated with new opioid use in older people with dementia. *Alzheimers Dement*. 2023;19(Suppl. 22): e077103. <https://doi.org/10.1002/alz.077103>.
170. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern Med*. 2015;175(3):401–7. <https://doi.org/10.1001/jamainternmed.2014.7663>.
171. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. *Aging Health*. 2008;4(3):311–20.
172. McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, et al. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. *Eur J Pharmacol*. 2009;605(1–3):145–52. <https://doi.org/10.1016/j.ejphar.2008.12.043>.
173. Poonawalla IB, Xu Y, Gaddy R, James A, Ruble M, Burns S, et al. Anticholinergic exposure and its association with dementia/Alzheimer's disease and mortality in older adults. *BMC Geriatr*. 2023;23(1):401. <https://doi.org/10.1186/s12877-023-04095-7>.
174. Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. *Clin Interv Aging*. 2009;4:225–33. <https://doi.org/10.2147/cia.s5358>.
175. Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. *Age Ageing*. 2014;43(5):604–15. <https://doi.org/10.1093/ageing/afu096>.
176. Welk B, Richardson K, Panicker JN. The cognitive effect of anticholinergics for patients with overactive bladder. *Nat Rev Urol*. 2021;18(11):686–700. <https://doi.org/10.1038/s41585-021-00504-x>.
177. Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. *BMJ*. 2018;361: k1315. <https://doi.org/10.1136/bmj.k1315>.
178. Kachru N, Holmes HM, Johnson ML, Chen H, Aparasu RR. Antimuscarinic use among older adults with dementia and overactive bladder: a medicare beneficiaries study. *Curr Med Res Opin*. 2021;37(8):1303–13. <https://doi.org/10.1080/03007995.2021.1920899>.
179. Griebing TL, Campbell NL, Mangel J, Staskin D, Herschorn S, Elsouada D, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PIL-LAR). *BMC Geriatr*. 2020;20(1):109. <https://doi.org/10.1186/s12877-020-1474-7>.
180. Edwards KR, O'Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. *J Am Geriatr Soc*. 2002;50(6):1165–6. <https://doi.org/10.1046/j.1532-5415.2002.50281.x>.
181. Zed PJ. Deprescribing proton pump inhibitors. *Can J Hosp Pharm*. 2018;71(5):291–2.
182. Northuis CA, Bell EJ, Lutsey PL, George KM, Gottesman RF, Mosley TH, et al. Cumulative use of proton pump inhibitors and risk of dementia: the atherosclerosis risk in communities study. *Neurology*. 2023;101(18):e1771–8. <https://doi.org/10.1212/WNL.0000000000207747>.
183. Clouston SAP, Shapira O, Kotov R, Lei L, Waszczuk M, Bromet EJ, et al. Proton pump inhibitors and the risk of severe cognitive impairment: the role of posttraumatic stress disorder. *Alzheimers Dement (N Y)*. 2017;3(4):579–83. <https://doi.org/10.1016/j.trci.2017.08.007>.
184. Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. *JAMA Neurol*. 2016;73(4):410–6. <https://doi.org/10.1001/jamaneurol.2015.4791>.
185. Tai SY, Chien CY, Wu DC, Lin KD, Ho BL, Chang YH, et al. Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan. *PLoS One*. 2017;12(2): e0171006. <https://doi.org/10.1371/journal.pone.0171006>.

186. Ahn N, Wawro N, Baumeister SE, Nolde M, Gerlach R, Tauscher M, et al. Time-varying use of proton pump inhibitors and cognitive impairment and dementia: a real-world analysis from Germany. *Drugs Aging*. 2023;40(7):653–63. <https://doi.org/10.1007/s40266-023-01031-7>.
187. Kumar R, Kumar A, Nordberg A, Langstrom B, Darreh-Shori T. Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme-A plausible missing link for their association with incidence of dementia. *Alzheimers Dement*. 2020;16(7):1031–42. <https://doi.org/10.1002/alz.12113>.
188. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. *JAMA*. 2013;310(22):2435–42. <https://doi.org/10.1001/jama.2013.280490>.
189. Swarnakari KM, Bai M, Manoharan MP, Raja R, Jamil A, Csendes D, et al. The effects of proton pump inhibitors in acid hypersecretion-induced Vitamin B12 deficiency: a systematic review (2022). *Cureus*. 2022;14(11): e31672. <https://doi.org/10.7759/cureus.31672>.
190. Lauer AA, Grimm HS, Apel B, Golobrodskaya N, Kruse L, Ratan-ski E, et al. Mechanistic link between Vitamin B12 and Alzheimer's disease. *Biomolecules*. 2022. <https://doi.org/10.3390/biom12010129>.
191. Kheloufi F, Frankel D, Kaspi E, Lepelley M, Mallaret M, Boucherie Q, et al. Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: a translational analysis. *Therapie*. 2018;73(3):273–81. <https://doi.org/10.1016/j.therap.2017.08.003>.
192. Puscas I, Coltau M, Baican M, Domuta G. Omeprazole has a dual mechanism of action: it inhibits both H(+)K(+)ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments). *J Pharmacol Exp Ther*. 1999;290(2):530–4.
193. Balakrishnan S, Bhargava VK, Pandhi P. Anticonvulsant activity of omeprazole in rats. *Epilepsy Res*. 2001;46(1):85–9. [https://doi.org/10.1016/S0920-1211\(01\)00262-5](https://doi.org/10.1016/S0920-1211(01)00262-5).
194. Poggetti V, Salerno S, Baglini E, Barresi E, Da Settimo F, Taliani S. Carbonic anhydrase activators for neurodegeneration: an overview. *Molecules*. 2022. <https://doi.org/10.3390/molecules27082544>.
195. Zhao W, Zhang J, Jia H, He Q, Cui J, Ding L, et al. Proton pump inhibitor-induced hypomagnesemia, a rare cause of reversible delirium: a case report with literature review. *Medicine (Baltimore)*. 2024;103(40): e39729. <https://doi.org/10.1097/MD.00000000000039729>.
196. Heckmann JG, Birklein F, Neundorfer B. Omeprazole-induced delirium. *J Neurol*. 2000;247(1):56–7. <https://doi.org/10.1007/s004150050011>.
197. Razdan A, Viswanathan R, Tusher A. Pantoprazole-induced delirium: review of a case and associated literature. *Case Rep Psychiatry*. 2018;2018:1232535. <https://doi.org/10.1155/2018/1232535>.
198. Otremba I, Wilczynski K, Szewieczek J. Delirium in the geriatric unit: proton-pump inhibitors and other risk factors. *Clin Interv Aging*. 2016;11:397–405. <https://doi.org/10.2147/CIA.S103349>.
199. Bentson J, Reza M, Winter J, Wilson G. Steroids and apparent cerebral atrophy on computed tomography scans. *J Comput Assist Tomogr*. 1978;2(1):16–23. <https://doi.org/10.1097/00004728-197801000-00003>.
200. Okuno T, Ito M, Konishi Y, Yoshioka M, Nakano Y. Cerebral atrophy following ACTH therapy. *J Comput Assist Tomogr*. 1980;4(1):20–3. <https://doi.org/10.1097/00004728-198002000-00004>.
201. Lupien S, Lecours AR, Lussier I, Schwartz G, Nair NP, Meaney MJ. Basal cortisol levels and cognitive deficits in human aging. *J Neurosci*. 1994;14(5 Pt 1):2893–903. <https://doi.org/10.1523/JNEUROSCI.14-05-02893.1994>.
202. Sapolsky RM. Glucocorticoids, stress and exacerbation of excitotoxic neuron death. *Seminars Neurosci*. 1994;6(5):323–31. <https://doi.org/10.1006/smns.1994.1041>.
203. Keenan PA, Jacobson MW, Soleymani RM, Newcomer JW. Commonly used therapeutic doses of glucocorticoids impair explicit memory. *Ann N Y Acad Sci*. 1995;761:400–2. <https://doi.org/10.1111/j.1749-6632.1995.tb31402.x>.
204. De Alcubierre D, Ferrari D, Mauro G, Isidori AM, Tomlinson JW, Pofi R. Glucocorticoids and cognitive function: a walk-through in endogenous and exogenous alterations. *J Endocrinol Invest*. 2023;46(10):1961–82. <https://doi.org/10.1007/s40618-023-02091-7>.
205. Brown ES, D JW, Frol A, Bobadilla L, Khan DA, Hanczyc M, et al. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. *Biol Psychiatry*. 2004;55(5):538–45. <https://doi.org/10.1016/j.biopsych.2003.09.010>.
206. Mrakotsky C, Forbes PW, Bernstein JH, Grand RJ, Bousvaros A, Szigethy E, et al. Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease. *J Int Neuropsychol Soc*. 2013;19(1):96–109. <https://doi.org/10.1017/S1355617712001014>.
207. Varney NR, Alexander B, MacIndoe JH. Reversible steroid dementia in patients without steroid psychosis. *Am J Psychiatry*. 1984;141(3):369–72. <https://doi.org/10.1176/ajp.141.3.369>.
208. Varney NR. A case of reversible steroid dementia. *Arch Clin Neuropsychol*. 1997;12(2):167–71.
209. Norra C, Arndt M, Kunert HJ. Steroid dementia: an overlooked diagnosis? *Neurology*. 2006;66(1):155. <https://doi.org/10.1212/01.wnl.0000203713.04232.82>.
210. Spannburg L, Reed H. Adverse cognitive effects of glucocorticoids: a systematic review of the literature. *Steroids*. 2023;200: 109314. <https://doi.org/10.1016/j.steroids.2023.109314>.
211. Koning A, van der Meulen M, Schaap D, Satoer DD, Vinkers CH, van Rossum EFC, et al. Neuropsychiatric adverse effects of synthetic glucocorticoids: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2024;109(6):e1442–51. <https://doi.org/10.1210/clinem/dgad701>.
212. Finsterer J. Transient tunnel vision and altered consciousness after a single dose of ibuprofen. *J Int Med Res*. 2022;50(9):3000605221126660. <https://doi.org/10.1177/03000605221126660>.
213. Bernstein AL, Werlin A. Pseudodementia associated with use of ibuprofen. *Ann Pharmacother*. 2003;37(1):80–2. <https://doi.org/10.1345/aph.1C218>.
214. Breitner JC, Haneuse SJ, Walker R, Dublin S, Crane PK, Gray SL, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. *Neurology*. 2009;72(22):1899–905. <https://doi.org/10.1212/WNL.0b013e3181a18691>.
215. in t, Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. *N Engl J Med*. 2001;345(21):1515–21. <https://doi.org/10.1056/NEJMoa010178>.
216. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. *Neurology*. 2002;59(6):880–6. <https://doi.org/10.1212/wnl.59.6.880>.
217. Khera T, Rangasamy V. Cognition and pain: a review. *Front Psychol*. 2021;12: 673962. <https://doi.org/10.3389/fpsyg.2021.673962>.
218. Migliore M, Habrant D, Sasso O, Albani C, Bertozzi SM, Armirrotti A, et al. Potent multitarget FAAH-COX inhibitors: design

- and structure-activity relationship studies. *Eur J Med Chem.* 2016;109:216–37. <https://doi.org/10.1016/j.ejmech.2015.12.036>.
219. Holt S, Paylor B, Boldrup L, Alajakku K, Vandevoorde S, Sundstrom A, et al. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. *Eur J Pharmacol.* 2007;565(1–3):26–36. <https://doi.org/10.1016/j.ejphar.2007.02.051>.
 220. Drozdal S, Lechowicz K, Szostak B, Rosik J, Kotfis K, Machoy-Mokrzynska A, et al. Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? Review of selected literature. *Pharmacol Res Perspect.* 2021;9(4): e00817. <https://doi.org/10.1002/prp2.817>.
 221. Wong M, Chowieczyk P, Kirkham B. Cardiovascular issues of COX-2 inhibitors and NSAIDs. *Aust Fam Physician.* 2005;34(11):945–8.
 222. Auriel E, Regev K, Korczyn AD. Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. *Handb Clin Neurol.* 2014;119:577–84. <https://doi.org/10.1016/B978-0-7020-4086-3.00038-2>.
 223. Gamulescu MA, Schalke B, Schuierer G, Gabel VP. Optic neuritis with visual field defect—possible Ibuprofen-related toxicity. *Ann Pharmacother.* 2006;40(3):571–3. <https://doi.org/10.1345/aph.1G451>.
 224. Onder G, Pellicciotti F, Gambassi G, Bernabei R. NSAID-related psychiatric adverse events: who is at risk? *Drugs.* 2004;64(23):2619–27. <https://doi.org/10.2165/00003495-200464230-00001>.
 225. Li D, Zhang J, Liu Q. Brain cell type-specific cholesterol metabolism and implications for learning and memory. *Trends Neurosci.* 2022;45(5):401–14. <https://doi.org/10.1016/j.tins.2022.01.002>.
 226. Sodero AO, Barrantes FJ. Pleiotropic effects of statins on brain cells. *Biochim Biophys Acta Biomembr.* 2020;1862(9): 183340. <https://doi.org/10.1016/j.bbmem.2020.183340>.
 227. Poitelon Y, Kopec AM, Belin S. Myelin fat facts: an overview of lipids and fatty acid metabolism. *Cells.* 2020. <https://doi.org/10.3390/cells9040812>.
 228. Svec A, Adameova A. Facts and ideas on statins with respect to their lipophilicity: a focus on skeletal muscle cells and bone besides known cardioprotection. *Mol Cell Biochem.* 2023;478(8):1661–7. <https://doi.org/10.1007/s11010-022-04621-y>.
 229. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. *Mitochondrion.* 2007;7(Suppl):S168–74. <https://doi.org/10.1016/j.mito.2007.03.002>.
 230. Munch J, Prasuhn J, Laugwitz L, Fung CW, Chung BH, Bellusci M, et al. Neuroimaging in primary coenzyme-Q(10)-deficiency disorders. *Antioxidants (Basel).* 2023. <https://doi.org/10.3390/antiox12030718>.
 231. Jamshidnejad-Tosaramandani T, Kashanian S, Al-Sabri MH, Krocianova D, Clemensson LE, Gentreau M, et al. Statins and cognition: modifying factors and possible underlying mechanisms. *Front Aging Neurosci.* 2022;14: 968039. <https://doi.org/10.3389/fnagi.2022.968039>.
 232. Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. *Transl Neurodegener.* 2018;7:5. <https://doi.org/10.1186/s40035-018-0110-3>.
 233. Orsi A, Sherman O, Woldelessie Z. Simvastatin-associated memory loss. *Pharmacotherapy.* 2001;21(6):767–9. <https://doi.org/10.1592/phco.21.7.767.34577>.
 234. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. *Pharmacotherapy.* 2003;23(12):1663–7. <https://doi.org/10.1592/phco.23.15.1663.31953>.
 235. Suraweera C, de Silva V, Hanwella R. Simvastatin-induced cognitive dysfunction: two case reports. *J Med Case Rep.* 2016;10:83. <https://doi.org/10.1186/s13256-016-0877-8>.
 236. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. *Pharmacotherapy.* 2003;23(7):871–80. <https://doi.org/10.1592/phco.23.7.871.32720>.
 237. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. *Pharmacotherapy.* 2009;29(7):800–11. <https://doi.org/10.1592/phco.29.7.800>.
 238. Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs [2-28-2012]. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs>. Accessed Dec 3, 2024;
 239. Guo Y, Zou G, Qi K, Jin J, Yao L, Pan Y, et al. Simvastatin impairs hippocampal synaptic plasticity and cognitive function in mice. *Mol Brain.* 2021;14(1):41. <https://doi.org/10.1186/s13041-021-00758-x>.
 240. Tan B, Rosenfeldt F, Ou R, Stough C. Evidence and mechanisms for statin-induced cognitive decline. *Expert Rev Clin Pharmacol.* 2019. <https://doi.org/10.1080/17512433.2019.1606711>.
 241. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. *Am J Med.* 2004;117(11):823–9. <https://doi.org/10.1016/j.amjmed.2004.07.041>.
 242. Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. *Ann Pharmacother.* 2012;46(4):549–57. <https://doi.org/10.1345/aph.1Q620>.
 243. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. *Mayo Clin Proc.* 2013;88(11):1213–21. <https://doi.org/10.1016/j.mayocp.2013.07.013>.
 244. Chadha B, Frishman WH. Review of the protective effects of statins on cognition. *Cardiol Rev.* 2021;29(6):328–35. <https://doi.org/10.1097/CRD.0000000000000359>.
 245. Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. *J Gen Intern Med.* 2015;30(3):348–58. <https://doi.org/10.1007/s11606-014-3115-3>.
 246. Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, et al. Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. *Eur J Prev Cardiol.* 2022;29(5):804–14. <https://doi.org/10.1093/eurjpc/zwab208>.
 247. Rea F, Corrao G, Mancina G. Risk of dementia during anti-hypertensive drug therapy in the elderly. *J Am Coll Cardiol.* 2024;83(13):1194–203. <https://doi.org/10.1016/j.jacc.2024.01.030>.
 248. Xu G, Bai F, Lin X, Wang Q, Wu Q, Sun S, et al. Association between antihypertensive drug use and the incidence of cognitive decline and dementia: a meta-analysis of prospective cohort studies. *Biomed Res Int.* 2017;2017:4368474. <https://doi.org/10.1155/2017/4368474>.

249. Bhanu C, Nimmons D, Petersen I, Orlu M, Davis D, Hussain H, et al. Drug-induced orthostatic hypotension: a systematic review and meta-analysis of randomised controlled trials. *PLoS Med*. 2021;18(11): e1003821. <https://doi.org/10.1371/journal.pmed.1003821>.
250. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. *Clin Auton Res*. 2011;21(2):69–72. <https://doi.org/10.1007/s10286-011-0119-5>.
251. Chen A, Ashburn MA. Cardiac effects of opioid therapy. *Pain Med*. 2015;16(Suppl 1):S27–31. <https://doi.org/10.1111/pme.12915>.
252. Mets TF. Drug-induced orthostatic hypotension in older patients. *Drugs Aging*. 1995;6(3):219–28. <https://doi.org/10.2165/00002512-199506030-00005>.
253. Rivasi G, Rafanelli M, Mossello E, Brignole M, Ungar A. Drug-related orthostatic hypotension: beyond anti-hypertensive medications. *Drugs Aging*. 2020;37(10):725–38. <https://doi.org/10.1007/s40266-020-00796-5>.
254. Buckley A, Carey D, Meaney JM, Kenny R, Harbison J. Is there an association between orthostatic hypotension and cerebral white matter hyperintensities in older people? The Irish longitudinal study on ageing. *JRSM Cardiovasc Dis*. 2020;9:2048004020954628. <https://doi.org/10.1177/2048004020954628>.
255. Kim JS, Lee S, Suh SW, Bae JB, Han JH, Byun S, et al. Association of low blood pressure with white matter hyperintensities in elderly individuals with controlled hypertension. *J Stroke*. 2020;22(1):99–107. <https://doi.org/10.5853/jos.2019.01844>.
256. Wei D, Wang Y, Yang X, Jin L. Association of white matter lesions with orthostatic hypotension. *Am J Transl Res*. 2022;14(4):2410–8.
257. Foster-Dingley JC, Moonen JE, van den Berg-Huijsmans AA, de Craen AJ, de Ruijter W, van der Grond J, et al. Lower blood pressure and gray matter integrity loss in older persons. *J Clin Hypertens (Greenwich)*. 2015;17(8):630–7. <https://doi.org/10.1111/jch.12550>.
258. Starmans NLP, Wolters FJ, Leeuwis AE, Bron EE, de Bresser J, Brunner-La Rocca HP, et al. Orthostatic hypotension, cognition and structural brain imaging in hemodynamically impaired patients. *J Neurol Sci*. 2024;461: 123026. <https://doi.org/10.1016/j.jns.2024.123026>.
259. Raber I, Belanger MJ, Farahmand R, Aggarwal R, Chiu N, Al Rifai M, et al. Orthostatic hypotension in hypertensive adults: harry goldblatt award for early career investigators 2021. *Hypertension*. 2022;79(11):2388–96. <https://doi.org/10.1161/HYPERTENSIONAHA.122.18557>.
260. Iseli R, Nguyen VTV, Sharmin S, Reijnierse EM, Lim WK, Maier AB. Orthostatic hypotension and cognition in older adults: A systematic review and meta-analysis. *Exp Gerontol*. 2019;120:40–9. <https://doi.org/10.1016/j.exger.2019.02.017>.
261. Bahat G, Ilhan B, Tufan A, Kilic C, Karan MA, Petrovic M. Hypotension under antihypertensive treatment and incident hospitalizations of nursing home residents. *Drugs Aging*. 2022;39(6):477–84. <https://doi.org/10.1007/s40266-022-00951-0>.
262. Centi J, Freeman R, Gibbons CH, Neargarder S, Canova AO, Cronin-Golomb A. Effects of orthostatic hypotension on cognition in Parkinson disease. *Neurology*. 2017;88(1):17–24. <https://doi.org/10.1212/WNL.0000000000003452>.
263. Ruiz Barrio I, Miki Y, Jaunmuktane ZT, Warner T, De Pablo-Fernandez E. Association between orthostatic hypotension and dementia in patients with parkinson disease and multiple system atrophy. *Neurology*. 2023;100(10):e998–1008. <https://doi.org/10.1212/WNL.0000000000201659>.
264. Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. *Ann Oncol*. 2019;30(12):1925–40. <https://doi.org/10.1093/annonc/mdz410>.
265. Krull KR, Hardy KK, Kahalley LS, Schuitema I, Kesler SR. Neurocognitive outcomes and interventions in long-term survivors of childhood cancer. *J Clin Oncol*. 2018;36(21):2181–9. <https://doi.org/10.1200/JCO.2017.76.4696>.
266. Janelins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. *Int Rev Psychiatry*. 2014;26(1):102–13. <https://doi.org/10.3109/09540261.2013.864260>.
267. Zachariae R, Mehlsen MY. Is chemotherapy associated with cognitive impairment? *Nat Rev Urol*. 2011;8(4):182–3. <https://doi.org/10.1038/nrurol.2011.29>.
268. Vannorsdall TD. Cognitive changes related to cancer therapy. *Med Clin North Am*. 2017;101(6):1115–34. <https://doi.org/10.1016/j.mcna.2017.06.006>.
269. Lindner OC, Phillips B, McCabe MG, Mayes A, Wearden A, Varese F, et al. A meta-analysis of cognitive impairment following adult cancer chemotherapy. *Neuropsychology*. 2014;28(5):726–40. <https://doi.org/10.1037/neu0000064>.
270. Fleming B, Edison P, Kenny L. Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management. *BMJ*. 2023;380: e071726. <https://doi.org/10.1136/bmj-2022-071726>.
271. Lawlor PG, Bush SH. Delirium in patients with cancer: assessment, impact, mechanisms and management. *Nat Rev Clin Oncol*. 2015;12(2):77–92. <https://doi.org/10.1038/nrclinonc.2014.147>.
272. Fischer R, Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. *Oxid Med Cell Longev*. 2015;2015: 610813. <https://doi.org/10.1155/2015/610813>.
273. Brandl S, Reindl M. Blood-Brain Barrier Breakdown in Neuroinflammation: Current In Vitro Models. *Int J Mol Sci*. 2023;24(16). <https://doi.org/10.3390/ijms241612699>.
274. Nokia MS, Anderson ML, Shors TJ. Chemotherapy disrupts learning, neurogenesis and theta activity in the adult brain. *Eur J Neurosci*. 2012;36(11):3521–30. <https://doi.org/10.1111/ejn.12007>.
275. Fritz-French C, Tyor W. Interferon-alpha (IFNalpha) neurotoxicity. *Cytokine Growth Factor Rev*. 2012;23(1–2):7–14. <https://doi.org/10.1016/j.cytogfr.2012.01.001>.